

## Medical Policy



### Title: **Noninvasive Techniques for the Evaluation and Monitoring of Patients with Chronic Liver Disease**

<b>Professional / Institutional</b>
Original Effective Date: September 16, 2016
Latest Review Date: December 23, 2024
Current Effective Date: December 29, 2022

**State and Federal mandates and health plan member contract language, including specific provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. To verify a member's benefits, contact [Blue Cross and Blue Shield of Kansas Customer Service](#).**

**The BCBSKS Medical Policies contained herein are for informational purposes and apply only to members who have health insurance through BCBSKS or who are covered by a self-insured group plan administered by BCBSKS. Medical Policy for FEP members is subject to FEP medical policy which may differ from BCBSKS Medical Policy.**

**The medical policies do not constitute medical advice or medical care. Treating health care providers are independent contractors and are neither employees nor agents of Blue Cross and Blue Shield of Kansas and are solely responsible for diagnosis, treatment and medical advice.**

**If your patient is covered under a different Blue Cross and Blue Shield plan, please refer to the Medical Policies of that plan.**

Populations	Interventions	Comparators	Outcomes
Individuals: • With chronic liver disease	Interventions of interest are: • FibroSURE serum panels	Comparators of interest are: • Liver biopsy • Noninvasive radiologic methods • Other multianalyte serum assays	Relevant outcomes include: • Test validity • Morbid events • Treatment-related morbidity
Individuals: • With chronic liver disease	Interventions of interest are: • Multianalyte serum assays for liver function assessment other than FibroSURE	Comparators of interest are: • Liver biopsy • Noninvasive radiologic methods • Other multianalyte serum assays	Relevant outcomes include: • Test validity • Morbid events • Treatment-related morbidity
Individuals:	Interventions of interest are:	Comparators of interest are: • Liver biopsy	Relevant outcomes include:

Populations	Interventions	Comparators	Outcomes
<ul style="list-style-type: none"> <li>With chronic liver disease</li> </ul>	<ul style="list-style-type: none"> <li>Transient elastography</li> </ul>	<ul style="list-style-type: none"> <li>Other noninvasive radiologic methods</li> <li>Multianalyte serum assays</li> </ul>	<ul style="list-style-type: none"> <li>Test validity</li> <li>Morbid events</li> <li>Treatment-related morbidity</li> </ul>
Individuals: <ul style="list-style-type: none"> <li>With chronic liver disease</li> </ul>	Interventions of interest are: <ul style="list-style-type: none"> <li>Multiparametric magnetic resonance imaging</li> </ul>	Comparators of interest are: <ul style="list-style-type: none"> <li>Liver biopsy</li> <li>Other noninvasive radiologic methods</li> <li>Multianalyte serum assays</li> </ul>	Relevant outcomes include: <ul style="list-style-type: none"> <li>Test validity</li> <li>Morbid events</li> <li>Treatment-related morbidity</li> </ul>
Individuals: <ul style="list-style-type: none"> <li>With chronic liver disease</li> </ul>	Interventions of interest are: <ul style="list-style-type: none"> <li>Noninvasive radiologic methods other than transient elastography or multiparametric magnetic resonance imaging for liver fibrosis measurement</li> </ul>	Comparators of interest are: <ul style="list-style-type: none"> <li>Liver biopsy</li> <li>Other noninvasive radiologic methods</li> <li>Multianalyte serum assays</li> </ul>	Relevant outcomes include: <ul style="list-style-type: none"> <li>Test validity</li> <li>Morbid events</li> <li>Treatment-related morbidity</li> </ul>

**DESCRIPTION**

Noninvasive techniques to monitor liver fibrosis are being investigated as alternatives to liver biopsy in patients with chronic liver disease. There are 2 options for noninvasive monitoring: (1) multianalyte serum assays with algorithmic analysis of either direct or indirect biomarkers; and (2) specialized radiologic methods, including magnetic resonance elastography, multiparametric magnetic resonance imaging (MRI), transient elastography, acoustic radiation force impulse imaging, and real-time transient elastography.

**OBJECTIVE**

The objective of this evidence review is to determine whether the use of noninvasive techniques for detecting liver fibrosis compared with liver biopsy can improve the net health outcome in patients with chronic liver disease.

**BACKGROUND**

**Biopsy for Chronic Liver Disease**

The diagnosis of non-neoplastic liver disease is often made from needle biopsy samples. In addition to establishing a disease etiology, liver biopsy can determine the degree of inflammation present and stage the degree of fibrosis. The degree of inflammation and fibrosis may be assessed by different scoring schemes. Most of these scoring schemes grade inflammation from 0 (no or minimal inflammation) to 4 (severe) and fibrosis from 0 (no fibrosis) to 4 (cirrhosis). There are several limitations to liver biopsy, including its invasive nature, small tissue sample size, and subjective grading system. Regarding small tissue sample size, liver

fibrosis can be patchy and thus missed on a biopsy sample, which includes only 0.002% of the liver tissue. A noninvasive alternative to liver biopsy would be particularly helpful, both to initially assess patients and then to monitor response to therapy. The implications of using liver biopsy as a reference standard are discussed in the Rationale.

### **Hepatitis C Virus**

Infection with hepatitis C virus (HCV) can lead to permanent liver damage. Prior to noninvasive testing, liver biopsy was typically recommended before the initiation of antiviral therapy. Repeat biopsies may be performed to monitor fibrosis progression. Liver biopsies are analyzed according to a histologic scoring system; the most commonly used one for HCV is the Metavir system, which scores the presence and degree of inflammatory activity and fibrosis. The fibrosis is graded from F0 to F4, with a Metavir score of F0 signifying no fibrosis and F4 signifying cirrhosis (which is defined as the presence throughout the liver of fibrous septa that subdivide the liver parenchyma into nodules, representing the final and irreversible form of the disease). The stage of fibrosis is the most important single predictor of morbidity and mortality in patients with hepatitis C. Biopsies for HCV are also evaluated according to the degree of inflammation present, referred to as the grade or activity level. For example, the Metavir system includes scores for necroinflammatory activity ranging from A0 to A3 (A0 = no activity, A1 = minimal activity, A2 = moderate activity, A3 = severe activity).

### **Hepatitis B Virus**

Most people who become infected with hepatitis B virus (HBV) recover fully, but a small portion develops chronic HBV, which can lead to permanent liver damage. As with HCV, identification of liver fibrosis is needed to determine timing and management of treatment, and liver biopsy is the criterion standard for staging fibrosis. The grading of fibrosis in HBV also uses the Metavir system.

### **Alcoholic Liver Disease**

Alcoholic liver disease (ALD) is the leading cause of liver disease in most Western countries. Histologic features of ALD usually include steatosis, alcoholic steatohepatitis (ASH), hepatocyte necrosis, Mallory bodies (tangled proteins seen in degenerating hepatocytes), a large polymorphonuclear inflammatory infiltrate, and, with continued alcohol abuse, fibrosis, and possibly cirrhosis. The grading of fibrosis is similar to the scoring system used in HCV. The commonly used Laënnec scoring system uses grades 0 to 4, with 4 being cirrhosis.

### **Nonalcoholic Fatty Liver Disease**

Nonalcoholic fatty liver disease (NAFLD) is defined as a condition that pathologically resembles ALD, but occurs in patients who are not heavy users of alcohol. Moreover, NAFLD may be associated with a variety of conditions, including obesity, diabetes, and dyslipidemia. The characteristic feature of NAFLD is steatosis. At the benign end of the disease spectrum, there is usually no appreciable inflammation, hepatocyte death, or fibrosis. In contrast, nonalcoholic steatohepatitis (NASH), which shows overlapping histologic features with ALD, is an intermediate form of liver damage, and liver biopsy may show steatosis, Mallory bodies, focal inflammation, and degenerating hepatocytes. NASH can progress to fibrosis and cirrhosis. A variety of histologic scoring systems have been used to evaluate NAFLD. The NAFLD Activity Score system for NASH includes scores for steatosis (0 to 3), lobular inflammation (0 to 3), and ballooning (0 to 2). Cases with scores of 5 or greater are considered NASH, while cases with

scores of 3 and 4 are considered borderline (probable or possible) NASH. The grading of fibrosis is similar to the scoring system used in hepatitis C. The commonly used Laënnec scoring system uses grades 0 to 4, with 4 being cirrhosis.

Of note, in 2023, NAFLD was renamed to metabolic dysfunction-associated steatotic liver disease (MASLD) due to concerns over exclusionary and stigmatizing language.<sup>1</sup> A consensus-driven process found that the new term better reflects the metabolic nature of the disease. Similarly, NASH was renamed to metabolic-dysfunction associated steatohepatitis (MASH). Additionally, a new term, metabolic and alcohol-related/associated liver disease (MetALD) was introduced to characterize disease with both metabolic dysfunction and significant alcohol intake. Due to this recent change, unless a publication specifically refers to MASLD or MASH, the abbreviations NAFLD and NASH, respectively, will continue to be used throughout this policy.

## **NONINVASIVE ALTERNATIVES TO LIVER BIOPSY**

### **Multianalyte Assays**

A variety of noninvasive laboratory tests are being evaluated as alternatives to liver biopsy. Biochemical tests can be broadly categorized into indirect and direct markers of liver fibrosis. Indirect markers include liver function tests such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), the ALT/AST ratio (also referred to as the AAR), platelet count, and prothrombin index. There has been a growing understanding of the underlying pathophysiology of fibrosis, leading to a direct measurement of the factors involved. For example, the central event in the pathophysiology of fibrosis is the activation of the hepatic stellate cell. Normally, stellate cells are quiescent, but are activated in the setting of liver injury, producing a variety of extracellular matrix (ECM) proteins. In normal livers, the rate of ECM production equals its degradation, but with fibrosis, production exceeds degradation. Metalloproteinases are involved in intracellular degradation of ECM, and a profibrogenic state exists when there is either a down-regulation of metalloproteinases or an increase in tissue inhibitors of metalloproteinases. Both metalloproteinases and tissue inhibitors of metalloproteinases can be measured in the serum, which directly reflects the fibrotic activity. Other direct measures of ECM deposition include hyaluronic acid or  $\alpha_2$ -macroglobulin.

While many studies have been done on these individual markers, or on groups of markers in different populations of patients with liver disease, there has been interest in analyzing multiple markers using mathematical algorithms to generate a score that categorizes patients according to the biopsy score. It is proposed that these algorithms can be used as alternatives to liver biopsy in patients with liver disease. The following proprietary, algorithm-based tests are commercially available in the U.S.

There are 3 different FibroSURE tests available depending on the indication for use: HCV FibroSURE, ASH FibroSURE, and NASH FibroSURE.

### **HCV FibroSURE**

The HCV FibroSURE uses a combination of 6 serum biochemical indirect markers of liver function plus age and sex in a patented algorithm to generate a measure of fibrosis and necroinflammatory activity in the liver that corresponds to the Metavir scoring system for stage (i.e., fibrosis) and grade (i.e., necroinflammatory activity). The measures are combined using a linear regression equation to produce a score between 0 and 1, with higher values corresponding to more severe disease. The biochemical markers include the readily available measurements of  $\alpha_2$ -macroglobulin, haptoglobin, bilirubin,  $\gamma$ -glutamyl transpeptidase, ALT, and apolipoprotein AI. Developed in France, the test has been clinically available in Europe under the name FibroTest since 2003; it is exclusively offered by LabCorp in the U.S. as HCV FibroSURE.

### **ASH FibroSURE**

ASH FibroSURE (ASH Test) uses a combination of 10 serum biochemical markers of liver function together with age, sex, height, and weight in a proprietary algorithm; the test is proposed to provide surrogate markers for liver fibrosis, hepatic steatosis, and ASH. The biochemical markers include  $\alpha_2$ -macroglobulin, haptoglobin, apolipoprotein AI, bilirubin,  $\gamma$ -glutamyl transpeptidase, ALT, AST, total cholesterol, triglycerides, and fasting glucose. The test has been available in Europe under the name AshTest™ (BioPredictive); the test is exclusively offered by LabCorp in the U.S. as ASH FibroSURE.

### **NASH FibroSURE**

NASH FibroSURE (NASH Test) uses a proprietary algorithm of the same 10 biochemical markers of liver function in combination with age, sex, height, and weight and is proposed to provide surrogate markers for liver fibrosis, hepatic steatosis, and NASH. The biochemical markers include  $\alpha_2$ -macroglobulin, haptoglobin, apolipoprotein AI, bilirubin,  $\gamma$ -glutamyl transpeptidase, ALT, AST, total cholesterol, triglycerides, and fasting glucose. The test has been available in Europe under the name NashTest™ (BioPredictive); the test is exclusively offered by LabCorp in the U.S. as NASH FibroSURE.

### **FIBROSpect II**

FIBROSpect II uses a combination of 3 markers that directly measure fibrogenesis of the liver, analyzed with a patented algorithm. The markers include hyaluronic acid, tissue inhibitor of metalloproteinase 1, and  $\alpha_2$ -macroglobulin. FIBROSpect II is offered exclusively by Prometheus Laboratories. The measures are combined using a logistic regression algorithm to generate a FIBROSpect II index score, ranging from 1 to 100 (or sometimes reported between 0 and 1), with higher scores indicating more severe disease.

### **Enhanced Liver Fibrosis Test**

The Enhanced Liver Fibrosis (ELF) test uses a proprietary algorithm to produce a score based on 3 serum biomarkers involved in matrix biology: hyaluronic acid, Procollagen III amino terminal peptide and tissue inhibitor of metalloproteinase 1. The manufacturer recommends the following cutoffs for interpretation for risk of development of cirrhosis or liver-related events in patients with NASH: <9.80 (lower risk) and  $\geq 11.30$  (higher risk).

## **Noninvasive Imaging Technologies**

Noninvasive imaging technologies to detect liver fibrosis or cirrhosis among patients with chronic liver disease are being evaluated as alternatives to liver biopsy. The noninvasive imaging technologies include transient elastography (e.g., FibroScan), magnetic resonance elastography, acoustic radiation force impulse (ARFI) imaging (e.g., Acuson S2000), multiparametric magnetic resonance imaging (MRI), and real-time tissue elastography (e.g., HI VISION Preirus). Noninvasive imaging tests have been used in combination with multianalyte serum tests such as FibroTest or FibroSURE with FibroScan.

### **Transient Elastography**

Transient elastography (FibroScan) uses a mechanical vibrator to produce mild amplitude and low-frequency (50 Hz) waves, inducing an elastic shear wave that propagates throughout the liver. Ultrasound tracks the wave, measuring its speed in kilopascals, which correlates with liver stiffness. Increases in liver fibrosis also increase liver stiffness and resistance of liver blood flow. Transient elastography does not perform as well in patients with ascites, higher body mass index, or narrow intercostal margins. Although FibroScan may be used to measure fibrosis (unlike liver biopsy), it does not provide information on necroinflammatory activity and steatosis, nor is it accurate during acute hepatitis or hepatitis exacerbations.

### **Acoustic Radiation Force Impulse Imaging**

ARFI imaging uses an ultrasound probe to produce an acoustic “push” pulse, which generates shear waves that propagate in tissue to assess liver stiffness. ARFI elastography evaluates the wave propagation speed (measured in meters per second) to assess liver stiffness. The faster the shear wave speed, the harder the object. ARFI technologies include Virtual Touch Quantification and Siemens Acuson S2000 system. ARFI elastography can be performed at the same time as a liver sonographic evaluation, even in patients with a significant amount of ascites.

### **Magnetic Resonance Elastography**

Magnetic resonance elastography uses a driver to generate 60-Hz mechanical waves on the patient’s chest wall. The magnetic resonance equipment creates elastograms by processing the acquired images of propagating shear waves in the liver using an inversion algorithm. These elastograms represent the shear stiffness as a pixel value in kilopascals. Magnetic resonance elastography has several advantages over ultrasound elastography, including: (1) the ability to analyze larger liver volumes; (2) the ability to analyze liver volumes of obese patients or patients with ascites; and (3) the ability to precisely analyze viscoelasticity using a 3-dimensional displacement vector.

### **Real-Time Tissue Elastography**

Real-time tissue elastography is a type of strain elastography that uses a combined autocorrelation method to measure tissue strain caused by manual compression or a person’s heartbeat. The relative tissue strain is displayed on conventional color B mode ultrasound images in real-time. Hitachi manufactures real-time tissue elastography devices, including the HI VISION Preirus. The challenge is to identify a region of interest while avoiding areas likely to introduce artifacts, such as large blood vessels, the area near the ribs, and the surface of the liver. Areas of low strain increase as fibrosis progresses and strain distribution becomes more complex. Various subjective and quantitative methods have been developed to evaluate the

results. Real-time tissue elastography can be performed in patients with ascites or inflammation. This technology does not perform as well in severely obese individuals.

### **Multiparametric Magnetic Resonance Imaging**

Multiparametric MRI combines proton density fat-fraction, T2\*, and T1 mapping. Proton density fat-fraction provides an assessment of hepatic fat content and can be used to determine the grade of liver steatosis. T1 relaxation times are used to assess increases in extracellular fluid, which correlates with the extent of fibrosis and inflammation of the liver. Hepatic iron quantification is measured through T2\* relaxation times as T1 relaxation times are decreased by excess iron in the liver tissue. LiverMultiScan® uses a clinical algorithm that accounts for an iron-corrected T1 value, based on the T2\* relaxation time, and proton density fat-fraction to assess the presence of fat, inflammation, and fibrosis.

### **REGULATORY STATUS**

In 2008 Acuson S2000™ Virtual Touch (Siemens AG), which provides ARFI imaging, was cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process (K072786).

In 2009, AIXPLORER® Ultrasound System (SuperSonic Imagine), which provides shear wave elastography, was cleared for marketing by the FDA through the 510(k) process (K091970).

In 2010, Hitachi HI VISION™ Preirus™ Diagnostic Ultrasound Scantier (Hitachi Medical Systems America), which provides real-time tissue elastography, was cleared for marketing by the FDA through the 510(k) process (K093466).

In 2013, FibroScan® (EchoSens), which uses transient elastography, was cleared for marketing by the FDA through the 510(k) process (K123806).

In June 2015, LiverMultiScan (Perspectum), which is a magnetic resonance diagnostic device software application, was cleared for marketing by the FDA through the 510(k) process (K143020).

In February 2017, ElastQ Imaging shear wave elastography (Royal Phillips) was cleared for marketing by the FDA through the 510(k) process (K163120).

In August 2021, ADVIA Centaur Enhanced Liver Fibrosis (ELF™) test (Siemens Healthcare) was cleared for marketing by the FDA through the 513(f)(2) De Novo review pathway (DEN190056). In 2018, the device had been granted a Breakthrough Device designation for predicting disease progression in patients with advanced fibrosis due to NAFLD.

In July 2023, the Enhanced Liver Fibrosis (ELF™) Test was granted a Breakthrough Device Designation to aid in the identification of advanced fibrosis ( $\geq$ F3) and cirrhosis (F4) in patients with NAFLD.

FDA product codes: IYO, LNH, QQB.

## POLICY

- A. A single FibroSURE multianalyte assay may be considered **medically necessary** for the initial evaluation of individuals with chronic liver disease.
- B. FibroSURE multianalyte assays are considered **experimental / investigational** for monitoring of individuals with chronic liver disease.
- C. Other multianalyte assays with algorithmic analyses are considered **experimental / investigational** for the initial evaluation or monitoring of individuals with chronic liver disease.
- D. Transient elastography (FibroScan) imaging may be considered **medically necessary** for the initial evaluation of individuals with chronic liver disease.
- E. Transient elastography (FibroScan) imaging is considered **experimental / investigational** for monitoring of individuals with chronic liver disease.
- F. The use of other noninvasive imaging, including, but not limited to, magnetic resonance elastography, multiparametric magnetic resonance imaging, acoustic radiation force impulse imaging (e.g., Acuson S2000), or real-time tissue elastography, is considered **experimental / investigational** for the initial evaluation or monitoring of individuals with chronic liver disease.

## POLICY GUIDELINES

- A. Multianalyte assays with algorithmic analyses (MAAAs) use the results from multiple assays of various types in an algorithmic analysis to determine and report a numeric score(s) or probability. The results of individual component assays are not reported separately.

**Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.**

## RATIONALE

This evidence review has been updated regularly with searches of the PubMed database. The most recent literature update was performed through September 27, 2024.

Evidence reviews assess whether a medical test is clinically useful. A useful test provides information to make a clinical management decision that improves the net health outcome. That is, the balance of benefits and harms is better when the test is used to manage the condition than when another test or no test is used to manage the condition.

The first step in assessing a medical test is to formulate the clinical context and purpose of the test. The test must be technically reliable, clinically valid, and clinically useful for that purpose.



Evidence reviews assess the evidence on whether a test is clinically valid and clinically useful. Technical reliability is outside the scope of these reviews, and credible information on technical reliability is available from other sources.

Promotion of greater diversity and inclusion in clinical research of historically marginalized groups (e.g., People of Color [African-American, Asian, Black, Latino and Native American]; LGBTQIA (Lesbian, Gay, Bisexual, Transgender, Queer, Intersex, Asexual); Women; and People with Disabilities [Physical and Invisible]) allows policy populations to be more reflective of and findings more applicable to our diverse members. While we also strive to use inclusive language related to these groups in our policies, use of gender-specific nouns (e.g., women, men, sisters, etc.) will continue when reflective of language used in publications describing study populations.

### **Noninvasive Testing for Chronic Liver Disease**

Liver biopsy is an imperfect reference standard. There is a high rate of sampling error, which can lead to underdiagnosis of liver disease.<sup>2,3</sup> These errors will bias estimates of performance characteristics of the noninvasive tests to which it is compared, and therefore such errors must be considered in appraising the body of evidence. Mehta et al (2009) estimated that even under the best scenario where sensitivity and specificity of liver biopsy are 90%, and the prevalence of significant disease (increased liver fibrosis, scored as Metavir  $\geq$ F2) is 40%; a perfect alternative marker would have calculated the area under the receiver operating characteristic (AUROC) curve of 0.90.<sup>4</sup> Therefore, the effectiveness of alternative technologies may be underestimated. In fact, when the accuracy of biopsy is presumed to be 80%, a comparative technology with an AUROC curve of 0.76 may actually have an AUROC curve of 0.93 to 0.99 for diagnosing true disease.

Due to a large number of primary studies published on this topic, this evidence review focuses on systematic reviews when available. The validation of multiple noninvasive tests is assessed individually in the following sections. Although options exist for performing systematic reviews with imperfect reference standards,<sup>5</sup> most available reviews did not use any correction for the imperfect reference.

A systematic review by Crossan et al (2015) was performed for the National Institute for Health Research.<sup>6</sup> The first objective of the review was to determine the diagnostic accuracy of different noninvasive liver tests compared with liver biopsy in the diagnosis and monitoring of liver fibrosis and cirrhosis in patients with hepatitis C virus (HCV), hepatitis B virus (HBV), nonalcoholic fatty liver disease (NAFLD), and alcoholic liver disease (ALD). Reviewers selected 302 publications and presentations from 1998 to April 2012. Patients with HCV were the most common population included in the studies while patients with ALD were the least common. FibroScan and FibroTest were the most commonly assessed tests across liver diseases. Aminotransferase to platelet ratio index (APRI) was also widely assessed in HBV and HCV but not in NAFLD or ALD. The estimates of diagnostic accuracy for each test by disease are discussed in further detail in the following sections. Briefly, for diagnosing significant fibrosis (stage  $\geq$ F2) in HCV, the summary sensitivities and specificities were: FibroScan, 79% and 83%; FibroTest, 68% and 72%; APRI (low cutoff), 82% and 57%; acoustic radiation force impulse (ARFI) imaging, 85% and 89%; HepaScore, 73% and 73%; FIBROSpect II, 78% and 71%; and FibroMeter, 79% and 73%, respectively. For diagnosing advanced fibrosis in HBV, the summary sensitivities and specificities were: FibroScan, 71% and 84% and FibroTest, 66% and 80%,

respectively. There are no established or validated cutoffs for fibrosis stages across the diseases for most tests. For FibroTest, established cutoffs exist, but were used inconsistently across studies. Test failures or reference standard(s) were frequently not captured in analyses. Most populations included in the studies were from tertiary care settings that have more advanced disease than the general population, which would overestimate the prevalence of the disease and diagnostic accuracy. These issues likely cause overestimates of sensitivities and specificities. The quality of the studies was generally rated as poor, with only 1.6% receiving a high-quality rating.

Houot et al (2016) reported on a systematic review funded by BioPredictive, the manufacturer of FibroTest.<sup>7</sup> This review included 71 studies published between January 2002 to February 2014 with over 12,000 participants with HCV and HBV comparing the diagnostic accuracy of FibroTest, FibroScan, APRI, and fibrosis-4 (FIB-4) index. Included studies directly compared the tests and calculated median differences in the AUROC curve using Bayesian methods. There was no evaluation of the methodologic quality of the included studies. The Bayesian difference in AUROC curve for significant fibrosis (stage  $\geq$ F2) between FibroTest and FibroScan was based on 15 studies and estimated to be 0.06 (95% credible interval [CrI], 0.02 to 0.09) favoring FibroTest. The difference in AUROC curve for cirrhosis for FibroTest versus FibroScan was based on 13 studies and estimated to be 0.00 (95% CrI, -0.04 to 0.04). The difference for advanced fibrosis between FibroTest and APRI was based on 21 studies and estimated to be 0.05 (95% CrI, 0.03 to 0.07); for cirrhosis, it was based on 14 studies and estimated to be 0.05 (95% CrI, 0.00 to 0.11), both favoring FibroTest.

## **MULTIANALYTE ASSAYS: FIBROSURE SERUM PANEL**

### **Clinical Context and Test Purpose**

The purpose of noninvasive testing in individuals with chronic liver disease is to detect liver fibrosis so that individuals can avoid the potential adverse events of an invasive liver biopsy and receive appropriate treatment. The degree of liver fibrosis is an important factor in determining the appropriate approach for managing individuals with liver disease (e.g., hepatitis, ALD, NAFLD).

The following PICO was used to select literature to inform this review.

### ***Populations***

The relevant population of interest is individuals with chronic liver disease.

### ***Interventions***

The test being considered is the FibroSURE serum panel.

### ***Comparators***

The following tests and practices are currently being used to diagnose chronic liver disease: liver biopsy, noninvasive radiologic methods, and other multianalyte serum assays.

### ***Outcomes***

The general outcomes of interest are test validity, morbid events, and treatment-related morbidity. Follow-up over months to years is of interest to the relevant outcomes.

## Study Selection Criteria

For the evaluation of the clinical validity of the tests within this review, studies that meet the following eligibility criteria were considered:

- Reported on the accuracy of the marketed version of the technology (including any algorithms used to calculate scores).
- Included a suitable reference standard (describe the reference standard).
- Patient/sample clinical characteristics were described.
- Patient/sample selection criteria were described.

## HEPATITIS C VIRUS

### Clinically Valid

A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

### Review of Evidence

Following the initial research into FibroSURE (patients with liver fibrosis who had undergone biopsy)<sup>8</sup>, the next step in the development of this test was a further evaluation of the algorithm in a cross-section of patients, including patients with HCV participating in large clinical trials before and after the initiation of antiviral therapy. A study by Poynard et al (2003) focused on patients with HCV participating in a randomized study of pegylated interferon and ribavirin.<sup>9</sup> From the 1530 participants, 352 patients with stored serum samples and liver biopsies at study entry and at 24-week follow-up were selected. The HCV FibroSURE score was calculated and then compared with the Metavir liver biopsy score. At a cutoff of 0.30, the HCV FibroSURE score had 90% sensitivity and 88% positive predictive value (PPV) for the diagnosis of Metavir F2 to F4 fibrosis; the specificity was 36%, and the negative predictive value (NPV) was 40%.

Poynard et al (2004) also evaluated discordant results in 537 patients who underwent liver biopsy and the HCV FibroSURE and ActiTest on the same day; discordance was attributed to either the limitations in the biopsy or serum markers.<sup>10</sup> In this study, cutoff values were used for individual Metavir scores (i.e., F0 to F4) and for combinations of Metavir scores (i.e., F0 to F1, F1 to F2). The definition of a significant discordance between FibroTest and ActiTest and biopsy scores was at least 2 stages or grades in the Metavir system. Discordance was observed in 29% of patients. Risk factors for failure of the HCV FibroSURE scoring system were as follows: the presence of hemolysis, inflammation, possible Gilbert syndrome, acute hepatitis, drugs inducing cholestasis, or an increase in transaminases. Discordance was attributable to markers in 2.4% of patients, to the biopsy in 18%, and unattributed in 8.2% of patients. As noted in 2 reviews, the bulk of the research on HCV FibroSURE was conducted by researchers with an interest in the commercialization of the algorithm.<sup>11,12</sup>

In the Crossan et al (2015) systematic review, FibroTest was the most widely validated commercial serum test.<sup>6</sup> Seventeen studies were included in the pooled estimate of the diagnostic accuracy of FibroTest for significant fibrosis (stage  $\geq$ F2) in HCV. With varying cutoffs for positivity between 0.32 and 0.53, the summary sensitivity in HCV was 68% (95% confidence interval [CI], 58% to 77%) and specificity was 72% (95% CI, 70% to 77%). Eight studies were included for cirrhosis (stage F4) in HCV. The cutoffs for positivity ranged from 0.56 to 0.74 and

the summary sensitivity and specificity were 60% (95% CI, 43% to 76%) and 86% (95% CI, 81% to 91%), respectively. Uninterpretable results were rare for tests based on serum markers.

### **Clinically Useful**

A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, more effective therapy, or avoid unnecessary therapy or testing.

### **Direct Evidence**

Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from randomized controlled trials (RCTs). The primary benefit of the FibroSURE (FibroTest in Europe) for HCV is the ability to avoid liver biopsy in patients without significant fibrosis. There are currently no such published studies to demonstrate the effect on patient outcomes.

The FibroTest has been used as an alternative to biopsy for the purposes of establishing trial eligibility in terms of fibrosis or cirrhosis; several trials with FibroTest (ION-1,-3; VALENCE; ASTRAL-2, -3, -4) have established the efficacy of HCV treatments.<sup>13,14,15,16,17,18</sup> For example, in the ASTRAL-2 and -3 trials, cirrhosis could be defined by a liver biopsy; a FibroScan or a FibroTest score of more than 0.75; or an APRI of more than 2.

These tests also need to be adequately compared with other noninvasive tests of fibrosis to determine their comparative efficacy. In particular, the proprietary, algorithmic tests should demonstrate superiority to other readily available, nonproprietary scoring systems to demonstrate that the tests improve health outcomes.

The FibroSURE test also has a potential effect on patient outcomes as a means to follow response to therapy. In this case, evidence needs to demonstrate that the use of the test for response to therapy impacts decision making and that these changes in management decisions lead to improved outcomes. It is not clear whether HCV FibroSURE could be used as an interval test in patients receiving therapy to determine whether an additional liver biopsy is necessary.

### **Chain of Evidence**

Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility.

## **ALCOHOLIC LIVER DISEASE AND ALCOHOLIC STEATOHEPATITIS**

### **Clinically Valid**

A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

### **Review of Evidence**

The diagnostic value of FibroSURE (FibroTest in Europe) has also been evaluated for the prediction of liver fibrosis in patients with ALD and NAFLD.<sup>19,20</sup> Thabut et al (2006) reported the development of a panel of biomarkers (ASH FibroSURE [ASH Test]) for the diagnosis of

alcoholic steatohepatitis (ASH) in patients with chronic ALD.<sup>21</sup> Biomarkers were initially assessed in a training group of 70 patients, and a panel was constructed using a combination of the 6 biochemical components of the FibroTest-ActiTest plus aspartate aminotransferase (AST). The algorithm was subsequently studied in 2 validation groups (1 prospective study for severe ALD, 1 retrospective study for nonsevere ALD) that included 155 patients and 299 controls. The severity of ASH (none, mild, moderate, severe) was blindly assessed from biopsy samples. In the validation groups, there were 28 (18%) cases of discordance between the diagnosis of ASH predicted by the ASH Test and biopsy; 10 (36%) were considered false-negatives of the ASH Test, and 11 were suspected failures of biopsy. Seven cases were indeterminate by biopsy. The AUROC curves were 0.88 and 0.89 in the validation groups. The median ASH Test value was 0.005 in controls, 0.05 in patients without or with mild ASH, 0.64 in the moderate ASH grade, and 0.84 in severe ASH grade 3. Using a cutoff value of 0.50, the ASH Test had a sensitivity of 80% and specificity of 84%, with PPVs and NPVs of 72% and 89%, respectively.

Several authors had an interest in the commercialization of this test, and no independent studies on the diagnostic accuracy of ASH FibroSURE (ASH Test) were identified. In addition, it is not clear if the algorithm used in this study is the same as that used in the currently commercially available test, which includes 10 biochemicals.

FibroTest has been studied in patients with ALD. In the Crossan et al (2015) systematic review, 1 study described the diagnostic accuracy of the FibroTest for significant fibrosis (stage  $\geq$  F2) or cirrhosis in ALD.<sup>6</sup> With a high cutoff for positivity (0.7), the sensitivity and specificity for advanced fibrosis were 55% (95% CI, 47% to 63%) and 93% (95% CI, 85% to 97%) and for cirrhosis were 91% (95% CI, 82% to 96%) and 87% (95% CI, 81% to 91%), respectively. With a low cutoff for positivity (0.3), the sensitivity and specificity for advanced fibrosis were 84% (95% CI, 77% to 89%) and 65% (95% CI, 55% to 75%), respectively. The sensitivity and specificity for cirrhosis were 100% (95% CI, 95% to 100%) and 50% (95% CI, 42% to 58%), respectively.

### **Clinically Useful**

A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, more effective therapy, or avoid unnecessary therapy or testing.

### **Direct Evidence**

Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from RCTs.

No studies were identified that assessed clinical outcomes following the use of the ASH FibroSURE (ASH Test) in ALD and ASH.

### **Chain of Evidence**

Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility.

## **NONALCOHOLIC FATTY LIVER DISEASE AND NONALCOHOLIC STEATOHEPATITIS**

### **Clinically Valid**

A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

### **Review of Evidence**

Poynard et al (2006) reported the development of a panel of biomarkers (NASH FibroSURE [NASH Test]) for the prediction of nonalcoholic steatohepatitis (NASH) in patients with NAFLD.<sup>22</sup> Biomarkers were initially assessed with a training group of 160 patients, and a panel was constructed using a combination of 13 of 14 parameters of the currently available test. The algorithm was subsequently studied in a validation group of 97 patients and 383 controls. Patients in the validation group were from a prospective multicenter study with hepatic steatosis at biopsy and suspicion of NAFLD. Histologic diagnoses used Kleiner et al's scoring system, with 3 classes for NASH (NASH, borderline NASH, no NASH). The main endpoint was steatohepatitis, defined as a histologic NASH score of 5 or greater. The AUROC curve for the validation group was 0.79 for the diagnosis of NASH, 0.69 for the diagnosis of borderline NASH, and 0.83 for the diagnosis of no NASH. Results showed a sensitivity of 33% and specificity of 94% for NASH, with a PPV and NPV of 66% and 81%, respectively. For borderline NASH or NASH, sensitivity was 88%, specificity 50%, PPV 74%, and NPV 72%. Clinically significant discordance (2 class difference) was observed in 8 (8%) patients. None of the 383 controls were considered to have NASH by NASH FibroSURE (NASH Test). Authors proposed that this test would be suitable for mass screening for NAFLD in patients with obesity and diabetes.

An independent study by Lassailly et al (2011) attempted to prospectively validate the NASH Test (along with the FibroTest, SteatoTest, and ActiTest) in a cohort of 288 patients treated with bariatric surgery.<sup>21</sup> Included were patients with severe or morbid obesity (body mass index, >35 kg/m<sup>2</sup>), at least 1 comorbidity for at least 5 years, and resistance to medical treatment. Excluded were patients with current excessive drinking, long-term consumption of hepatotoxic drugs, and positive screening for chronic liver diseases including hepatitis. Histology and biochemical measurements were centralized and blinded to other characteristics. The NASH Test provided a 3-category score for no NASH (0.25), possible NASH (0.50), and NASH (0.75). The prevalence of NASH was 6.9%, while the prevalence of NASH or possible NASH was 27%. The concordance rate between the histologic NASH score and the NASH Test was 43.1%, with a weak  $\kappa$  reliability test (0.14). In 183 patients categorized as possible NASH by the NASH Test, 124 (68%) were classified as no NASH by biopsy. In 15 patients categorized as NASH by the NASH Test, 7 (47%) were no NASH and 4 (27%) were possible NASH by biopsy. The NPV of the NASH Test for possible NASH or NASH was 47.5%. Authors suggested that the power of this study to validate agreement between the NASH Test and biopsy was low, due to the low prevalence of NASH. However, the results showed poor concordance between the NASH Test and biopsy, particularly for intermediate values.

In the Crossan et al (2015) systematic review, 4 studies were included in the pooled estimate of the diagnostic accuracy of FibroTest for advanced fibrosis (stage  $\geq 3$ ) in NAFLD.<sup>6</sup> The summary sensitivities and specificities were 40% (95% CI, 24% to 58%) and 96% (95% CI, 91% to 98%), respectively. Only 1 study included reported accuracy for cirrhosis, with sensitivity and specificity of 74% (95% CI, 54%, to 87%) and 92% (95% CI, 88% to 95%), respectively.

### **Clinically Useful**

A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, more effective therapy, or avoid unnecessary therapy or testing.

### **Direct Evidence**

Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from RCTs.

No studies were identified that assessed clinical outcomes following the use of the NASH FibroSURE (NASH Test) in NAFLD and NASH.

### **Chain of Evidence**

Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility.

## **HEPATITIS B VIRUS**

### **Clinically Valid**

A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

### **Review of Evidence**

While most multianalyte assay studies that have identified fibrosis have been conducted in patients with HCV, studies are also being conducted in patients with chronic HBV.<sup>23,24</sup> In a study, Park et al (2013) compared liver biopsy with the FibroTest results obtained on the same day from 330 patients who had chronic HBV.<sup>25</sup> Discordance was found in 30 (9.1%) patients for whom the FibroTest underestimated fibrosis in 25 patients and overestimated it in 5 patients. Those with Metavir liver fibrosis stage F3 or F4 (15.4%) had a significantly higher discordance rate than those with stages F1 or F2 (3.0%;  $p < .001$ ). The only independent factor for discordance on multivariate analysis was a Metavir stage F3 or F4 on liver biopsy ( $p < .001$ ).

Salkic et al (2014) conducted a meta-analysis of studies on the diagnostic accuracy of FibroTest in chronic HBV.<sup>26</sup> Included in the meta-analysis were 16 studies ( $n=2494$ ) on liver fibrosis diagnosis and 13 studies ( $n=1754$ ) on cirrhosis diagnosis. There was strong evidence of heterogeneity in the 16 fibrosis studies and evidence of heterogeneity in the cirrhosis studies. For significant liver fibrosis (Metavir F2 to F4) diagnosis using all of the fibrosis studies, the AUROC curve was 0.84 (95% CI, 0.78 to 0.88). At the recommended FibroTest threshold of 0.48 for a significant liver fibrosis diagnosis, the sensitivity was 60.9%, specificity was 79.9%, and the diagnostic odds ratio (OR) was 6.2. For liver cirrhosis (Metavir F4) diagnosis using all of the cirrhosis studies, the AUROC curve was 0.87 (95% CI, 0.85 to 0.9). At the recommended FibroTest threshold of 0.74 for cirrhosis diagnosis, the sensitivity was 61.5%, specificity was 90.8%, and the diagnostic OR was 15.7. While the results demonstrated FibroTest may be useful in excluding a diagnosis of cirrhosis in patients with chronic HBV, the ability to detect significant fibrosis and cirrhosis and exclude significant fibrosis is suboptimal.

Xu et al (2014) reported on a systematic review and meta-analysis of studies assessing biomarkers to detect fibrosis in HBV.<sup>27</sup> Included in the analysis of FibroTest were 11 studies (N=1640). In these 11 studies, AUROC curves ranged from 0.69 to 0.90. Heterogeneity in the studies was statistically significant.

In the Crossan et al (2015) systematic review, 6 studies were included in the pooled estimate of the diagnostic accuracy of FibroTest for significant fibrosis (stage  $\geq$ F2) in HBV.<sup>6</sup> The cutoffs for positivity ranged from 0.40 to 0.48, and the summary sensitivities and specificities were 66% (95% CI, 57% to 75%) and 80% (95% CI, 72% to 86%), respectively. The accuracy for diagnosing cirrhosis in HBV was based on 4 studies with cutoffs for positivity ranging from 0.58 to 0.74; sensitivities and specificities were 74% (95% CI, 25% to 96%) and 90% (95% CI, 83% to 94%), respectively.

### **Clinically Useful**

A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, more effective therapy, or avoid unnecessary therapy or testing.

### **Direct Evidence**

Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from RCTs.

There are no studies evaluating the effect of this test on outcomes for patients with HBV. Of note, some researchers have suggested that different markers (e.g., HBV FibroSURE) may be needed for this assessment in patients with hepatitis B.<sup>28</sup>

### **Chain of Evidence**

Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility.

### **Section Summary: FibroSURE Serum Panel**

For individuals who have chronic liver disease who receive FibroSURE serum panels, the evidence includes systematic reviews of more than 30 observational studies (>5000 patients). FibroSURE has been studied in populations with viral hepatitis, NAFLD, and ALD. There are established cutoffs, although they were not consistently used in validation studies. Given these limitations and the imperfect reference standard, it is difficult to interpret performance characteristics. However, for the purposes of deciding whether a patient has severe fibrosis or cirrhosis, FibroSURE results provide data sufficiently useful to determine therapy. Specifically, FibroSURE has been used as an alternative to biopsy to establish eligibility regarding the presence of fibrosis or cirrhosis in several RCTs that showed the efficacy of HCV treatments, which in turn demonstrated that the test can identify patients who would benefit from therapy.

## **MULTIANALYTE SERUM ASSAYS OTHER THAN FIBROSURE**



### **Clinical Context and Test Purpose**

The purpose of noninvasive testing in individuals with chronic liver disease is to detect liver fibrosis so that individuals can avoid the potential adverse events of an invasive liver biopsy and receive appropriate treatment. The degree of liver fibrosis is an important factor in determining the appropriate approach for managing individuals with liver disease (e.g., hepatitis, ALD, NAFLD).

The following PICO was used to select literature to inform this review.

### ***Populations***

The relevant population of interest is individuals with chronic liver disease.

### ***Interventions***

The tests being considered are multianalyte serum assays (other than FibroSURE).

### ***Comparators***

The following tests and practices are currently being used to diagnose chronic liver disease: liver biopsy, noninvasive radiologic methods, and other multianalyte serum assays.

### ***Outcomes***

The general outcomes of interest are test validity, morbid events, and treatment-related morbidity. Follow-up over months to years is of interest to the relevant outcomes.

### **Study Selection Criteria**

For the evaluation of the clinical validity of the tests within this review, studies that meet the following eligibility criteria were considered:

- Reported on the accuracy of the marketed version of the technology (including any algorithms used to calculate scores).
- Included a suitable reference standard (describe the reference standard).
- Patient/sample clinical characteristics were described.
- Patient/sample selection criteria were described.

## **FIBROSPECT II**

### **Clinically Valid**

A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

### **Review of Evidence**

Patel et al (2004) investigated the use of serum markers in an initial training set of 294 patients with HCV and further validated the resulting algorithm in a validation set of 402 patients.<sup>29</sup> The algorithm was designed to distinguish between no or mild fibrosis (F0 to F1) and moderate-to-severe fibrosis (F2 to F4). With the prevalence of F2 to F4 disease of 52% and a cutoff value of 0.36, the PPVs and NPVs were 74.3% and 75.8%, respectively.

The published studies for this combination of markers continue to focus on test characteristics such as sensitivity, specificity, and accuracy.<sup>30,31,32</sup> In Crossan et al (2015), the summary

diagnostic accuracy for detecting significant fibrosis (stage  $\geq$ F2) in 5 studies of HCV with FIBROSpect II, with cutoffs ranging from 42 to 72, was 78% (95% CI, 49% to 93%) and the summary specificity was 71% (95% CI, 59% to 80%).<sup>6</sup>

### **Clinically Useful**

A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, more effective therapy, or avoid unnecessary therapy or testing.

### **Direct Evidence**

Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from RCTs.

The issues of effect on patient outcomes are similar to those discussed for the FibroSURE (FibroTest in Europe). No studies were identified in the published literature in which the results of the FIBROSpect test were actively used in the management of the patient.

### **Chain of Evidence**

Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility.

Because the clinical validity of FIBROSpect has not been established, a chain of evidence supporting the clinical utility of this test for this population cannot be constructed.

## **OTHER MULTIANALYTE SCORING SYSTEMS**

### **Clinically Valid**

A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

### **Review of Evidence**

Other scoring systems have been developed, including FIB-4, NAFLD fibrosis score (NFS), APRI, AST/ALT ratio, combined body mass index, AST/ALT ratio and diabetes status (BARD), and Enhanced Liver Fibrosis (ELF). The ELF test combines measurements of biomarkers into a proprietary algorithm to produce a score. The other scoring systems use a simple nonproprietary formula that can be calculated at the bedside to produce a score for the prediction of fibrosis. Tables 1 and 2 summarize the characteristics and results of systematic reviews that have assessed the diagnostic accuracy of various noninvasive scoring systems. There are no established cutoffs for ruling in or ruling out advanced fibrosis for most tests. In the systematic reviews, 2 cutoffs were analyzed for each test (as selected by the authors); a lower threshold to rule out advanced fibrosis and a higher threshold to rule in advanced fibrosis. Patients that fall between the 2 thresholds are classified as "indeterminate" risk for whom a liver biopsy may be considered. Castellana et al (2021) conducted a meta-analytic head-to-head comparison between FIB-4 and NFS and found no significant differences regarding relative diagnostic OR, positive likelihood ratio, and negative likelihood ratio.<sup>33</sup> FIB-4 was associated with fewer indeterminate findings compared to NFS. Mozes et al (2021) found that FibroScan, a

transient elastography test, outperformed all of the serum-based tests.<sup>34</sup> Sharma et al (2021) qualitatively evaluated the diagnostic performance of ELF in patients with chronic liver disease.<sup>35</sup> Mozes et al (2023) found that all index tests evaluated (NFS, FIB-4, and FibroScan) performed as well as histologically assessed fibrosis in predicting clinical outcomes in patients with NAFLD.<sup>36</sup> Similarly, Lopez Torrez et al (2024) concluded that, compared to biopsy, the following noninvasive scoring systems demonstrated better diagnostic accuracy for predicting liver fibrosis severity in individuals with MASLD: FIB-4 for any fibrosis, FibroMeter for significant fibrosis, ELF for advanced fibrosis, and FIB-4 for cirrhosis.<sup>37</sup> Lastly, a Cochrane review by Huttman et al (2024) found that in patients with HCV, a FIB-4 cut-off of 1.45 can be used to rule out advanced fibrosis.<sup>38</sup>

**Table 1. Characteristics of Systematic Reviews Assessing NonInvasive Scoring Systems**

Study	Dates	Studies	N (range)	Population	Index Tests	Reference Standard
Lopez Torrez (2024) <sup>37</sup> ,	NR	138	46,514 (31 to 3202)	MASLD	APRI FIB-4 NFS BARD score FibroMeter FibroTest ELF	Histology
Huttman et al (2024) <sup>38</sup> ,	up to 2021	84	107,583 (NR)	HCV	FIB-4	Histology
Mozes et al (2023) <sup>36</sup> ,	up to 2020	25	2518 (NR)	NAFLD	FibroScan FIB-4 NFS	Histology
Castellana et al (2021) <sup>33</sup> ,	2012-2020	18	12,604 (102 to 3202)	NAFLD	FIB-4 NFS	Histology
Mozes et al (2021) <sup>34</sup> ,	Up to 2020	37	5735 (13 to 1063)	NAFLD	FibroScan FIB-4 NFS APRI AST/ALT	Histology
Sharma et al (2021) <sup>35</sup> ,	Up to 2020	36	NR (38 to 3202)	Chronic liver disease (NAFLD, ALD, hepatitis, mixed etiologies)	ELF	Histology

ALD: alcoholic liver disease; ALT: alanine aminotransferase; APRI: AST-to-platelet ratio; AST: aspartate aminotransferase; BARD: body mass index, aspartate aminotransferase/alanine aminotransferase ratio; diabetes score; ELF: Enhanced Liver Fibrosis; FIB-4: fibrosis-4 index; NAFLD: nonalcoholic fatty liver disease; NFS: NAFLD fibrosis score; NR: not reported.

**Table 2. Results of Systematic Reviews Assessing the Diagnostic Accuracy of NonInvasive Scoring Systems**

<b>Index Test (Threshold)</b>	<b>Studies/Sample Size</b>	<b>Index Test Threshold (low, high)</b>	<b>AUROC (95% CI) Sensitivity (95% CI) Specificity (95% CI)</b>
Lopez Torrez (2024) <sup>37,</sup>			Any Fibrosis
APRI	3 (1535)	-	0.76 77% (61% to 88%) 64% (48% to 78%)
FIB-4	5 (2172)	-	0.77 77% (61% to 87%) 68% (57% to 78%)
NFS	5 (2725)	-	0.71 66% (62% to 70%) 73% (64% to 81%)
			Significant fibrosis
APRI	14 (4845)	-	0.76 63% (53% to 72%) 79% (69% to 86%)
FIB-4	15 (5222)	-	0.75 64% (52% to 74%) 76% (66% to 84%)
NFS	14 (3031)	-	0.81 69% (56% to 79%) 80% (71% to 88%)
BARD score	6 (1275)	-	0.77 66% (45% to 82%) 75% (65% to 83%)
FibroMeter	4 (651)	-	0.88 68% (48% to 82%) 89% (80% to 95%)
FibroTest	4 (640)	-	0.86 72% (28% to 94%) 85% (45% to 98%)
			Advanced Fibrosis
APRI	33 (10,341)	-	0.78 60% (50% to 69%) 82% (76% to 87%)
FIB-4	43 (16,519)	-	0.81 60% (52% to 68%) 87% (82% to 91%)

<b>Index Test (Threshold)</b>	<b>Studies/Sample Size</b>	<b>Index Test Threshold (low, high)</b>	<b>AUROC (95% CI) Sensitivity (95% CI) Specificity (95% CI)</b>
NFS	43 (17,946)	-	0.81 62% (53% to 70%) 85% (79% to 90%)
BARD score	21 (4911)	-	0.73 72% (64% to 79%) 63% (54% to 71%)
FibroMeter	12 (3863)	-	0.84 74% (68% to 79%) 82% (76% to 87%)
FibroTest	6 (1620)	-	0.78 40% (15% to 72%) 93% (73% to 99%)
ELF	6 (4200)	-	0.87 79% (68% to 87%) 84% (75% to 90%)
			Cirrhosis
APRI	3 (2632)	-	0.72 47% (3% to 84%) 87% (50% to 98%)
FIB-4	4 (1886)	-	0.83 69% (43% to 86%) 87% (57% to 97%)
NFS	3 (2478)	-	0.69 63% (58% to 68%) 84% (73% to 91%)
Huttman et al (2024) <sup>38,</sup>			Advanced Fibrosis (i.e., Stages F3 to F4)
FIB-4	Low index: 39 (86,907) High index: 24 (81,350)	1.45, 3.25	NR For $\geq 1.45$ ( $< 1.45$ ): 81.1% (75.6% to 85.6%); 62.3% (57.4% to 66.9%) For $\geq 3.25$ (vs $< 3.25$ ): 41.4% (33.0% to 50.4%); 92.6% (89.5% to 94.9%)
Mozes et al (2023) <sup>36,</sup>			Fibrosis (i.e., Stages F0 to F4)
FibroScan	NR (2518)	-	0.76 (0.70 to 0.83) at 5 years For $\geq 10.0$ kPa (vs $< 10$ kPa): 70.6% (62% to 79%); 66.0% (64% to 69%) For $\geq 20.0$ kPa (vs $< 20$ kPa): 29.4% (19% to 40%); 92.0% (90% to 93%)

<b>Index Test (Threshold)</b>	<b>Studies/Sample Size</b>	<b>Index Test Threshold (low, high)</b>	<b>AUROC (95% CI) Sensitivity (95% CI) Specificity (95% CI)</b>
FIB-4	NR (2275)	-	0.74 (0.64 to 0.82) at 5 years For $\geq 1.30$ (vs $< 1.3$ ): 82.6% (77% to 88%); 54.5% (52% to 58%) For $> 2.67$ (vs $\leq 2.67$ ): 41.3% (32% to 51%); 87.7% (86% to 90%)
NFS	NR (2040)	-	0.70 (0.63 to 0.80) at 5 years For $\geq -1.455$ (vs $< -1.455$ ): 78.9% (72% to 84%); 46.5% (44% to 51%) For $> 0.676$ (vs $\leq 0.676$ ): 31.6% (22% to 43%); 84.6% (82% to 87%)
Castellana et al (2021) <sup>33,</sup>			Advanced Fibrosis (i.e., Stages F3 to F4)
FIB-4	14 (9968)	1.3, 2.67	NR 65% (51% to 77%) 93% (89% to 96%)
NFS	14 (9113)	-1.455, 0.676	NR 61% (45% to 76%) 93% (89% to 96%)
Mozes et al (2021) <sup>34,</sup>			Advanced Fibrosis (i.e., Stages F3 to F4)
FibroScan	NR (5489)	7.4, 12.1	0.85 (0.84 to 0.86) 84% (81% to 87%) 87% (85% to 88%)
FIB-4	NR (5393)	0.88, 2.31	0.76 (0.74 to 0.77) 80% (76% to 83%) 79% (77% to 81%)
NFS	NR (3248)	-2.55, 0.28	0.73 (0.71 to 0.75) 74% (70% to 79%) 78% (76% to 81%)
APRI	NR (5477)	-	0.70 (0.69 to 0.72) <sup>a</sup> NE NE
AST/ALT	NR (5434)	-	0.64 (0.62 to 0.65) <sup>a</sup> NE NE
Sharma et al (2021) <sup>35,</sup>			Advanced Fibrosis
ELF - HCV	11 (NR)	Varied among studies	AUROC range, 0.773 (0.697 to 0.848) to 0.98 (0.93 to 1.00)

<b>Index Test (Threshold)</b>	<b>Studies/Sample Size</b>	<b>Index Test Threshold (low, high)</b>	<b>AUROC (95% CI) Sensitivity (95% CI) Specificity (95% CI)</b>
ELF - HBV	4 (NR)	Varied among studies	AUROC range, 0.69 (0.63 to 0.75) to 0.86 (0.81 to 0.92)
ELF - NAFLD	7 (NR)	Varied among studies	AUROC range, 0.78 (0.70 to 0.89) to 0.97 (no CI reported)
ELF - ALD	3 (NR)	Varied among studies	AUROC range, 0.92 (0.89 to 0.96) to 0.944 (0.836 to 1.000)
ELF - mixed etiology	7 (NR)	Varied among studies	AUROC range, 0.63 (no CI reported) to 0.91 (0.88 to 0.95)

ALD: alcoholic liver disease; ALT: alanine aminotransferase; APRI: aminotransferase-to-platelet ratio index; AST: aspartate aminotransferase; AUROC: area under the receiver operating characteristic; BARD: body mass index, aspartate aminotransferase/alanine aminotransferase ratio; CI: confidence interval; ELF: enhanced liver fibrosis; FIB-4: fibrosis-4 index; HBV: hepatitis B virus; HCV: hepatitis C virus; NAFLD: nonalcoholic fatty liver disease; NE: not evaluated; NFS: NAFLD fibrosis score; NR: not reported.

<sup>a</sup>Diagnostic performance not further evaluated after modest performance on AUROC.

The APRI requires only the serum level of AST and the number of platelets as part of its calculation.<sup>39</sup> Using an optimized cutoff value derived from a training set and validation set of patients with HCV, authors have reported that the NPV for fibrosis was 86% and that the PPV was 88%. In Crossan et al (2015), APRI was frequently evaluated and has been tested in HCV, HBV, NAFLD, and ALD.<sup>6</sup> The summary diagnostic accuracies are in Table 3.

**Table 3. Diagnostic Accuracy for Aminotransferase to Platelet Ratio Index**

<b>Disease</b>	<b>Metavir Stage</b>	<b>Cutoff</b>	<b>Studies</b>	<b>Sensitivity, % (95% CI)</b>	<b>Specificity, % (95% CI)</b>
HCV	≥F2 (significant)	Low: 0.4 to 0.7	47	82 (77 to 86)	57 (49 to 65)
HCV	≥F2 (significant)	High: 1.5	36	39 (32 to 47)	92 (89 to 95)
HCV	F4 (cirrhosis)	Low: 0.75 to 1	24	77 (73 to 81)	78 (74 to 81)
HCV	F4 (cirrhosis)	High: 2	19	48 (41 to 56)	94 (91 to 95)
HBV	≥F2 (significant)	Low: 0.4 to 0.6	8	80 (68 to 88)	65 (52 to 77)
HBV	≥F2 (significant)	High: 1.5	6	37 (22 to 55)	93 (85 to 97)
HBV	F4 (cirrhosis)	Low: 1	4	58 (49 to 66)	76 (70 to 81)
HBV	F4 (cirrhosis)	High: 2	3	24 (8 to 52)	91 (83 to 96)
NAFLD	≥F3 (significant)	0.5 to 1.0	4	40 (7 to 86)	82 (78 to 86)
NAFLD	F4 (cirrhosis)	0.54 and NA	2	78 (71 to 99)	71 (30 to 93)
ALD	≥F2 (significant)	Low: 0.5	2	72 (60 to 82)	46 (33 to 60)

Disease	Metavir Stage	Cutoff	Studies	Sensitivity, % (95% CI)	Specificity, % (95% CI)
ALD	≥F2 (significant)	High: 1.5	2	54 (42 to 66)	78 (64 to 88)
ALD	F4 (cirrhosis)	High: 2.0	1	40 (22 to 61)	62 (41 to 79)

Adapted from Crossan et al (2015).<sup>6</sup>

ALD: alcoholic liver disease; APRI: aspartate aminotransferase-platelet ratio index; CI: confidence interval; HBV: hepatitis B virus; HCV: hepatitis C virus; NA: not available; NAFLD: nonalcoholic fatty liver disease.

Giannini et al (2006) reported that the use of the AST/ALT ratio and platelet counts in a diagnostic algorithm would have avoided liver biopsy in 69% of patients with chronic hepatitis C and would have correctly identified the absence or presence of significant fibrosis in 80.5% of these cases.<sup>40</sup> In Crossan et al (2015), the cutoffs for the positivity of AST/ALT ratio for diagnosis of significant fibrosis (stage ≥F2) varied from 0.6 to 1 in 7 studies.<sup>6</sup> Summary sensitivity and specificity were 44% (95% CI, 27% to 63%) and 71% (95% CI, 62% to 78%), respectively. Thirteen studies used a cutoff of 1 to estimate the diagnostic accuracy of cirrhosis with the AST/ALT ratio, and summary sensitivity and specificity were 49% (95% CI, 39% to 59%) and 87% (95% CI, 75% to 94%), respectively.

A number of studies have compared HCV FibroSURE (FibroTest) and other noninvasive tests of fibrosis with biopsy using receiver operating characteristic (ROC) analysis. For example, Bourliere et al (2006) reported on the validation of FibroSURE (FibroTest) and found that, based on ROC analysis, FibroSURE (FibroTest) was superior to APRI for identifying significant fibrosis, with AUROC curves of 0.81 and 0.71, respectively.<sup>41</sup> A prospective multicenter study by Zarksi et al (2012) compared 9 of the best-evaluated blood tests in 436 patients with HCV and found similar performance for HCV FibroSURE (FibroTest), FibroMeter, and HepaScore (ROC curve, 0.84, 0.86, 0.84, respectively).<sup>42</sup> These 3 tests were significantly superior to the 6 other tests, with 70% to 73% of patients considered well-classified according to a dichotomized score (F0/F1 vs ≥F2). The number of “theoretically avoided liver biopsies” for the diagnosis of significant fibrosis was calculated to be 35.6% for HCV FibroSURE (FibroTest). To improve diagnostic accuracy, algorithms that combine HCV FibroSURE (FibroTest) with other tests (e.g., APRI) are also being evaluated.<sup>42,43,44</sup> One of these, the sequential algorithm for fibrosis evaluation, combines the APRI and FibroTest. Crossan et al (2015) reported that the algorithm has been assessed in 4 studies of HCV for diagnosing both significant fibrosis (stage ≥F2) and cirrhosis.<sup>6</sup> Summary sensitivity and specificity for significant fibrosis were estimated to be 100% (95% CI, 100% to 100%) and 81% (95% CI, 80% to 83%), respectively. The summary sensitivity and specificity for cirrhosis were 74% (95% CI, 42% to 92%) and 93% (95% CI, 91% to 94%), respectively.

Rosenberg et al (2004) developed a scoring system based on an algorithm combining hyaluronic acid, amino-terminal propeptide of type III collagen, and tissue inhibitors of metalloproteinase 1.<sup>45</sup> This test is manufactured by Siemens Healthcare as the ELF Test.<sup>46</sup> The algorithm was developed in a test set of 400 patients with a wide variety of chronic liver diseases and then validated in another 521 patients. The algorithm was designed to discriminate between no or mild fibrosis and moderate-to-severe fibrosis. The NPV for fibrosis was 92%.



Younossi et al (2021) evaluated the diagnostic value of ELF to assess liver fibrosis in patients with NAFLD.<sup>47</sup> This was a retrospective, cross-sectional study including 829 patients; 462 had transient elastography data and 463 had liver biopsy data. A significant increase in ELF scores was correlated in patients with advanced fibrosis by biopsy or transient elastography. The AUROC for ELF for identifying fibrosis was 0.81 (95% CI, 0.77 to 0.85) with biopsy as the reference standard and 0.79 (95% CI, 0.75 to 0.82) with transient elastography as the reference standard. Predictive combinations of ELF and FIB-4 scores were additionally evaluated. For ELF score  $\geq 7.2$  with a FIB-4 score  $\geq 0.74$ , the sensitivity and NPV were 92.5% (95% CI, 87.4% to 97.5%) and 95.1% (95% CI, 91.8% to 98.4%), respectively, for ruling out fibrosis. For ELF score  $\geq 9.8$  with a FIB-4 score  $\geq 2.9$ , the specificity and PPV were 99.7% (95% CI, 99.1% to 100%) and 95.0% (95% CI, 85.5% to 100%), respectively, for ruling in fibrosis.

The FIB-4 index was developed in a cohort of patients with HCV and is similar to APRI in that it uses a simple nonproprietary formula to produce a score for the prediction of fibrosis, incorporating patient age, AST level, ALT level, and platelet count. In the original cohort studied by Sterling et al (2006)<sup>48</sup>, a low cutoff score of  $< 1.45$  had an NPV of 90% for advanced fibrosis whereas a high cutoff score  $> 3.25$  had a 97% specificity and PPV of 65% for advanced fibrosis. Overall, 70% of patients were stratified  $< 1.45$  or  $> 3.25$  and represented potential cases that could have avoided liver biopsy with a corresponding diagnostic accuracy of 86%. In a comparative study by Vallet-Pichard et al (2007) in patients with HCV utilizing the same cutoff values, an NPV of 94.7% with a sensitivity of 74.3% and a specificity of 80.1% and a PPV of 82.1% with a specificity of 98.2% and sensitivity of 37.6% were reported.<sup>49</sup> When the diagnostic performance of FIB-4 was compared against FibroTest (FibroSure in the U.S.), the exclusion of severe fibrosis and the detection of severe fibrosis were found to agree between the tests in 92.1% and 76.0% of cases, respectively.

Yan et al (2020) evaluated the diagnostic value of total bile acid-to-cholesterol ratio (TBA/TC) as a serum marker for cirrhosis and fibrosis in chronic HBV-infected patients without cholestasis<sup>50</sup>. This was a cross-sectional study including 667 patients. In a multivariate analysis, TBA/TC was independently correlated with cirrhosis in the study population (OR, 1.102; 95% CI, 1.085 to 1.166). ROC curve analyses yielded similar areas under the curve (AUCs) for TBA/TC, APRI, and FIB-4 at 0.87, 0.84, and 0.80, respectively. For diagnosing cirrhosis, the specificity and PPV of TBA/TC (83.33%, 91.10%) were higher than those of APRI (73.61%, 87.20%). The AUC of TBA/TC that distinguished significant liver cirrhosis was 2.70. In another multivariate analysis, TBA/TC was also independently correlated with significant fibrosis (OR, 1.040; 95% CI, 1.001 to 1.078). The AUC of TBA/TC that distinguished significant liver fibrosis was 0.70. Among 32 patients who also had a liver biopsy performed, TBA/TC was significantly higher in both fibrosis and cirrhosis as well as significantly correlated with fibrosis stage ( $p < .001$  for all).

Cluppel et al reported on a 5-year observational study comparing ARFI elastography, FIB-4 score, and liver biopsy.<sup>51</sup> A total of 113 patients were included, and histology showed that 26.5% had high-grade fibrosis and 16.8% had liver cirrhosis. The AUROC for predicting liver-related death within 5 years (9.7%,  $n=11$ ) was 0.80 (95% CI, 0.68 to 0.92) for ARFI elastography, 0.79 (95% CI, 0.66 to 0.92) for biopsy, and 0.66 (95% CI, 0.53 to 0.79) for FIB-4; ARFI outperformed FIB-4 ( $p=.02$ ), but did not significantly differ from biopsy ( $p=.83$ ). The AUROC for liver decompensation or variceal bleeding (13.3%,  $n=15$ ) was 0.86 (95% CI, 0.76 to

0.94) for ARFI, which was significantly higher than for biopsy at 0.71 (95% CI, 0.56 to 0.86;  $p=.02$ ) and FIB-4 at 0.67 (95% CI, 0.54 to 0.80;  $p=.003$ ). For the event of hepatocellular carcinoma, there was no significant difference between ARFI and biopsy ( $p=.33$ ) or FIB-4 ( $p=.14$ ).

### Clinically Useful

A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, more effective therapy, or avoid unnecessary therapy or testing.

### Direct Evidence

Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from RCTs. The primary benefit of the multivariate serum assays is the ability to avoid liver biopsy.

A systematic review and meta-analysis conducted by Cianci et al (2022) evaluated the use of noninvasive biomarkers for the prediction of all-cause and cardiovascular mortality in patients with NAFLD.<sup>52</sup> Of 24 studies included in the review, noninvasive scoring systems were assessed in 16 studies, 4 of which had adequate data for meta-analysis based on review criteria that required 2 or more studies reporting the same outcome measure using equivalent cut-off values and statistical methods in a similar study population. All of the studies included in the meta-analysis studies were retrospective (N=9,725; n range=320 to 4,680), and NAFLD diagnosis was based on liver biopsy or clinical diagnosis. The mean duration of follow-up ranged from 9 to 20 years in 3 of the studies and was not reported in the fourth study, but the total study duration was 17 years. A total of 1,697 deaths were reported in the 4 studies. Results of the meta-analyses appear in Table 4. Although high scores were associated with an increased risk of mortality relative to low scores across all scoring systems, the evidence is limited by the small number of included studies and high heterogeneity and imprecision for some estimates.

**Table 4. Pooled Diagnostic Accuracy of Noninvasive Scoring Systems for Prediction of All-Cause and Cardiovascular Mortality in Patients with NAFLD**

Scoring System	Number of Studies	Comparison (Score Cut-off)	Pooled HR (95% CI)
<b>All-cause mortality</b>			
NFS	4	High (>0.676) vs. Low (< -1.455)	3.07 (1.62 to 5.83; I <sup>2</sup> =76%)
NFS	4	Intermediate (-1.455 to 0.676) vs. Low (< -1.455)	1.91 (1.18 to 3.09; I <sup>2</sup> =82%)
FIB-4	3	High (>2.67) vs. Low (<1.30)	3.06 (1.54 to 6.07; I <sup>2</sup> =73%)
FIB-4	3	Intermediate (1.30 to 2.67) vs. Low (<1.30)	1.60 (1.33 to 1.91; I <sup>2</sup> =0%)
APRI	3	High (>1.5) vs. Low (<0.5)	1.90 (1.32 to 2.73; I <sup>2</sup> =0%)

Scoring System	Number of Studies	Comparison (Score Cut-off)	Pooled HR (95% CI)
APRI	3	Intermediate (0.5 to 1.5) vs. Low (<0.5)	0.98 (0.76 to 1.26; I <sup>2</sup> =0%)
BARD	2	High (4) vs. Low (0 to 1)	2.87 (1.27 to 6.46; I <sup>2</sup> =45%)
BARD	2	Intermediate (2 to 3) vs. Low (0 to 1)	1.64 (1.21 to 2.23; I <sup>2</sup> =0%)
<b>Cardiovascular mortality</b>			
NFS	2	High (>0.676) vs. Low (< -1.455)	3.09 (1.78 to 5.34; I <sup>2</sup> =0%)
NFS	2	Intermediate (-1.455 to 0.676) vs. Low (< -1.455)	2.12 (1.41 to 3.17; I <sup>2</sup> =0%)

Adapted from Cianci et al 2022<sup>52</sup>.

ALT: alanine aminotransferase; APRI: aminotransferase-to-platelet ratio index; AST: aspartate aminotransferase; BARD: body mass index, AST/ALT ratio and diabetes status; CI: confidence interval; FIB-4: fibrosis-4 index; HR: hazard ratio; NAFLD: nonalcoholic fatty liver disease; NFS: NAFLD fibrosis score.

Sanyal et al (2019) reported on findings of 2, phase 2b, placebo-controlled trials of simtuzumab in NASH in patients with bridging fibrosis (F3; n=217) or compensated cirrhosis (F4; n=258) that assessed patients with liver biopsy and serum biomarker tests, including ELF, APRI, FibroSure/FibroTest, and the FIB-4 index.<sup>53</sup> Laboratory screening was conducted at baseline and every 3 months during the trials. The trials were terminated after 96 weeks due to simtuzumab inefficacy, at which point data from treatment groups were combined for analysis. In patients with bridging fibrosis, an increased risk of progression to cirrhosis was observed with higher baseline levels of all serum fibrosis tests (p<.001). Change in the ELF score over time was also associated with progression to cirrhosis (p<.001). For a cutoff score of 9.76, progression to cirrhosis had a reported hazard ratio (HR) of 4.12 (95% CI, 2.14 to 7.93; p<.001). For patients with compensated cirrhosis, higher levels of baseline biomarker tests were also associated with liver-related clinical events in 19% of patients, such as ascites, hepatic encephalopathy, newly diagnosed varices, esophageal variceal bleed, increase in Child-Pugh and/or model for end-stage liver disease (MELD) score, or death (p<.001 to .006). While the manufacturer of the test differentiates moderate from severe fibrosis with a cutoff ELF score of 9.8, current National Institute for Health and Care Excellence guidelines for NAFLD recommend reserving a diagnosis of advanced fibrosis to NAFLD patients with an ELF score of 10.51 or greater, limiting the clinical significance of these findings.<sup>54</sup> Furthermore, serum fibrosis test results were not directly used in patient management in the simtuzumab trials.

### Chain of Evidence

Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility.

### Section Summary: Multianalyte Serum Assays Other Than FibroSURE

For individuals who have chronic liver disease who receive multianalyte serum assays for liver function assessment other than FibroSURE, the evidence includes a number of observational

studies and systematic reviews of those studies. Studies have frequently included varying cutoffs, some of which were standardized and others not validated. Cutoff thresholds have often been modified over time, may be specific to certain patient populations, and in some cases, guideline recommendations differ from cutoffs designated by manufacturers and those utilized in studies. Authors of one meta-analysis concluded that when compared to biopsy, the following noninvasive scoring systems demonstrated better diagnostic accuracy for predicting liver fibrosis severity in individuals with MASLD: FIB-4 for any fibrosis, FibroMeter for significant fibrosis, ELF for advanced fibrosis, and FIB-4 for cirrhosis. A comparison of transient elastography to various serum-based tests found that the former was superior in detecting fibrosis, and a meta-analysis of 4 studies found higher multianalyte scores associated with an increased risk of mortality relative to lower scores, but the evidence is limited by the small number of included studies and high heterogeneity and imprecision for some estimates. Given these limitations and the imperfect reference standard, it is difficult to interpret performance characteristics. There is no direct evidence that other multianalyte serum assays improve health outcomes; further, it is not possible to construct a chain of evidence for clinical utility due to the lack of sufficient evidence on clinical validity. FIBROSpect II has been studied in populations with HCV. Cutoffs for positivity varied across studies and were not well validated. The methodologic quality of the validation studies was generally poor. There is no direct evidence that FIBROSpect II improves health outcomes.

## **NONINVASIVE IMAGING: TRANSIENT ELASTOGRAPHY**

### **Clinical Context and Test Purpose**

The purpose of noninvasive testing in individuals with chronic liver disease is to detect liver fibrosis so that individuals can avoid the potential adverse events of an invasive liver biopsy and receive appropriate treatment. The degree of liver fibrosis is an important factor in determining the appropriate approach for managing individuals with liver disease (e.g., hepatitis, ALD, NAFLD).

The following PICO was used to select literature to inform this review.

### ***Populations***

The relevant population of interest is individuals with chronic liver disease.

### ***Interventions***

The test being considered is transient elastography.

### ***Comparators***

The following tests and practices are currently being used to diagnose chronic liver disease: liver biopsy, other noninvasive radiologic methods, and multianalyte serum assays.

### ***Outcomes***

The general outcomes of interest are test validity, morbid events, and treatment-related morbidity. Follow-up over months to years is of interest to the relevant outcomes.

### Study Selection Criteria

For the evaluation of the clinical validity of the tests within this review, studies that meet the following eligibility criteria were considered:

- Reported on the accuracy of the marketed version of the technology (including any algorithms used to calculate scores).
- Included a suitable reference standard (describe the reference standard).
- Patient/sample clinical characteristics were described.
- Patient/sample selection criteria were described.

### Clinically Valid

A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

### Review of Evidence

There is extensive literature on the use of transient elastography (e.g., FibroScan) to gauge liver fibrosis and cirrhosis. Summaries of systematic reviews are shown in Tables 5 and 6. Brener (2015) performed a health technology assessment summarizing many of the systematic reviews below.<sup>55</sup> The assessment focused on reviews of the diagnostic accuracy and effect on patient outcomes of transient elastography for liver fibrosis in patients with HCV, HBV, NAFLD, ALD, or cholestatic diseases. Fourteen systematic reviews of transient elastography with biopsy reference standard shown below were included in the Brener assessment, summarizing more than 150 primary studies.<sup>56,57,58,59,60,61,62,63,64,65,66,67,68,69</sup> There was variation in the underlying cause of liver disease and the cutoff values of transient elastography stiffness used to define Metavir stages in the systematic reviews. There did not appear to be a substantial difference in diagnostic accuracy for 1 disease over any other. The reviews demonstrated that transient elastography has good diagnostic accuracy compared with biopsy for the assessment of liver fibrosis and steatosis.

Crossan et al (2015) found that FibroScan was the noninvasive liver test most assessed in validation studies across liver diseases (37 studies in HCV, 13 in HBV, 8 in NAFLD, 6 in ALD).<sup>6</sup> Cutoffs for positivity for fibrosis staging varied between diseases and were frequently not prespecified or validated: HCV, 5.2 to 10.1 kilopascal (kPa) in the 37 studies for Metavir stages  $\geq$ F2; HBV, 6.3 to 8.9 kPa in 13 studies for stages  $\geq$ F2; NAFLD, 7.5 to 10.4 kPa in 8 studies for stages  $\geq$ F3; ALD, 11.0 to 12.5 kPa in 4 studies for stages  $\geq$ F3. Summary sensitivities and specificities by disease are shown in Table 6. The overall sensitivity and specificity for cirrhosis including all diseases (65 studies; cutoffs range, 9.2 to 26.5 kPa) were 89% (95% CI, 86% to 91%) and 89% (95% CI, 87% to 91%), respectively. The rate of uninterpretable results, when reported, with FibroScan (due to <10 valid measurements; success rate, <60%; interquartile range, >30%) was 8.5% in HCV and 9.6% in NAFLD.

**Table 5. Transient Elastography Systematic Review Characteristics**

Study	Dates	Studies	N	Population
Bota et al (2013) <sup>56</sup> ,	To May 2012	13	1163	Chronic hepatitis
Cai et al (2021) <sup>70</sup> ,	To Mar 2019	62	NR	ALD, NAFLD
Chon et al (2012) <sup>57</sup> ,	2002 to Mar 2011	18	2772	HBV

<b>Study</b>	<b>Dates</b>	<b>Studies</b>	<b>N</b>	<b>Population</b>
Crossan et al (2015) <sup>6</sup> ,	1998 to Apr 2012	66	NR	HCV, HBV, NAFLD, ALD
Friedrich-Rust et al (2008) <sup>58</sup> ,	2002 to Apr 2007	50	11,275	All causes of liver disease
Geng et al (2016) <sup>71</sup> ,	To Jan 2015	57	10,569	Multiple causes of liver disease
Jiang et al (2018) <sup>72</sup> ,	To Dec 2017	11	1735	NAFLD
Kwok et al (2014) <sup>59</sup> ,	To Jun 2013	22	1047	NAFLD
Li et al (2016) <sup>73</sup> ,	Jan 2003 to Nov 2014	27	4386	HBV
Njei et al (2016) <sup>74</sup> ,	To Jan 2016	6	756	HCV/HIV coinfection
Pavlov et al (2015) <sup>75</sup> ,	To Aug 2014	14	834	ALD
Poynard et al (2011) <sup>61</sup> ,	Feb 2001 to Dec 2010	18	2714	HBV
Shaheen et al (2007) <sup>62</sup> ,	Jan 1997 to Oct 2006	12	1981	HCV
Shi et al (2014) <sup>63</sup> ,	To May 2013	9	1771	All causes of steatosis
Steadman et al (2013) <sup>64</sup> ,	2001 to Jun 2011	64	6028	HCV, HBV, NAFLD, CLD, liver transplant
Stebbing et al (2010) <sup>65</sup> ,	NR, prior to Feb 2009	22	4625	All causes of liver disease
Talwalkar et al (2007) <sup>66</sup> ,	To Jan 2027	9	2083	All causes of liver disease
Tsochatzis et al (2011) <sup>67</sup> ,	To May 2009	40	7661	All causes of liver disease
Tsochatzis et al (2014) <sup>68</sup> ,	1998 to Apr 2012	302	NR	HCV, HBV, ALD, NAFLD
Xu et al (2015) <sup>76</sup> ,	To Dec 2013	19	3113	HBV
Xue-Ying (2020) <sup>69</sup> ,	Jan 2008 to Dec 2018	81	32,694	HBV

ALD: alcoholic liver disease; CLD: chronic liver disease; HBV: hepatitis B virus; HCV: hepatitis C virus; HIV: human immunodeficiency virus; NAFLD: nonalcoholic fatty liver disease; NR: not reported.

**Table 6. Transient Elastography Systematic Reviews Diagnostic Accuracy Results**

Study	Population	Significant Fibrosis (i.e., Metavir Stages F2 to F4)		Cirrhosis (i.e., Metavir Stage F4)	
		Studies/ Sample Size	AUROC (95% CI) Sensitivity (95% CI) Specificity (95% CI)	Studies/ Sample Size	AUROC (95% CI) Sensitivity (95% CI) Specificity (95% CI)
Bota et al (2013) <sup>56</sup> ,	Multiple diseases	10/1016	0.87 (0.83 to 0.89) 78% (72% to 83%) 84% (75% to 90%)	13/1163	0.93 (0.91 to 0.95) 89% (80% to 94%) 87% (82% to 91%)
	HCV			4/NR	NR 92% (78% to 97%) 86% (82% to 90%)
Cai et al (2021) <sup>70</sup> ,	ALD/NAFLD	40/2569	0.86 (0.83 to 0.89) 77% (73% to 81%) 82% (78% to 86%)	34/914	0.95 (0.92 to 0.96) 91% (87% to 94%) 86% (83% to 89%)
Chon et al (2012) <sup>57</sup> ,	Chronic HBV	12/2000	0.86 (0.86 to 0.86) 74.3% (NR) 78.3% (NR)	16/2614	0.93 (0.93 to 0.93) 84.6% (NR) 81.5% (NR)
Crossan et al(2015) <sup>6</sup> ,	HCV	37/NR	NR 79% (74% to 84%) 83% (77% to 88%)	36/NR	NR 89% (84% to 92%) 91% (89% to 93%)
	HBV	13/NR	NR 71% (62% to 78%) 84% (74% to 91%)	19/NR	NR 86% (79% to 91%) 85% (78% to 89%)
	NAFLD			4/NR	NR 96% (83% to 99%) 89% (85% to 92%)
	ALD	1/NR	NR 81% (70% to 88%) 92% (76% to 98%)	4/NR	NR 87% (64% to 96%) 82% (67% to 91%)
Friedrich- Rust (2008) <sup>58</sup> ,	Multiple diseases	25/3685	0.84 (0.82 to 0.86) NR NR	25/4557	0.94 (0.93 to 0.95) NR NR
	HCV	NR	0.84 (0.80 to 0.86) NR NR		
Geng et al (2016) <sup>71</sup> ,	Multiple diseases				0.93 (NR) 81% (79% to 83%) 88% (87% to 89%)
Jiang et al (2018) <sup>72</sup> ,	NAFLD	10/NR	0.85 (0.82 to 0.88) 77% (70% to 84%) 80% (74% to 84%)	11/NR	0.96 (0.93 to 0.97) 90% (73% to 97%) 91% (87% to 94%)

		<b>Significant Fibrosis (i.e., Metavir Stages F2 to F4)</b>		<b>Cirrhosis (i.e., Metavir Stage F4)</b>	
Kwok et al(2014) <sup>59,</sup>	NAFLD	7/800	0.83 (0.79 to 0.87) 0.79 (0.72 to 0.84) 0.75 (0.71 to 0.79)	57/10,569	0.96 (0.94 to 0.99) 92% (82% to 97%) 92% (86% to 98%)
Li et al (2016) <sup>73,</sup>	HBV	19/NR	0.88 (0.85 to 0.91) 81% (76% to 85%) 82% (71% to 87%)	24/NR	0.93 (0.91 to 0.95) 86% (82% to 90%) 88% (84% to 90%)
Njei et al (2016) <sup>74,</sup>	HCV/HIV	6/756	NR 97% (82% to 91%) 64% (45% to 79%)	6/756	NR 90% (74% to 91%) 87% (80% to 92%)
Pavlov et al(2015) <sup>75,</sup>	ALD	7/338	NR 94% (86% to 97%) 89% (76% to 95%)	7/330	NR 95% (87% to 98%) 71% (56% to 82%)
Poynard et al(2011) <sup>61,</sup>	HBV	4/NR	0.84 (0.78 to 0.89) NR NR	NR	0.93 (0.87 to 0.99) NR NR
Shaheen et al(2007) <sup>62,</sup>	HCV	4/NR	0.84 (0.78 to 0.89) NR NR	NR	0.93 (0.87 to 0.99) NR NR
Shi et al(2014) <sup>63,</sup>	No summary statistics reported. Concluded that transient elastography controlled attenuation parameter has good sensitivity and specificity for diagnosing steatosis, but it has limited utility.				
Steadman et al(2013) <sup>64,</sup>	Multiple diseases	45/NR	0.88 (0.84 to 0.90) 80% (76% to 83%) 81% (77% to 85%)	49/NR	0.94 (0.91 to 0.96) 86% (82% to 89%) 89% (87% to 91%)
	HBV	5/710	0.81 (0.78 to 0.84) 77% (68% to 84%) 72% (55% to 85%)	8/1092	0.86 (0.82 to 0.89) 67% (57% to 75%) 87% (83% to 91%)
	HCV	13/2732	0.89 (0.86 to 0.91) 76% (61% to 86%) 86%	12/2887	0.94 (0.92 to 0.96) 85% (77% to 91%) 91% (87% to 93%)



		<b>Significant Fibrosis (i.e., Metavir Stages F2 to F4)</b>		<b>Cirrhosis (i.e., Metavir Stage F4)</b>	
			(77% to 92%)		
	NAFLD	5/630	0.78 (0.74 to 0.82) 77% (70% to 83%) 75% (70% to 79%)	4/469	0.96 (0.94 to 0.97) 92% (77% to 98%) 95% (88% to 98%)
Stebbing et al(2010) <sup>65</sup> ,	Multiple diseases	17/3066	NR 72% (71% to 72%) 82% (82% to 83%)	17/4052	NR 84% (84% to 85%) 95% (94% to 95%)
Talwalkar et al(2007) <sup>66</sup> ,	Multiple diseases	7/>1100	0.87 (0.83 to 0.91) 70% (67% to 73%) 84% (80% to 88%)	9/2083	0.96 (0.94 to 0.98) 87% (84% to 90%) 91% (89% to 92%)
	Multiple diseases	31/5919	NR 79% (74% to 82%) 78% (72% to 83%)	30/6530	NR 83% (79% to 86%) 89% (87% to 91%)
Tsochatzis et al(2011) <sup>67</sup> ,	HCV	14/NR	NR 78% (71% to 84%) 80% (71% to 86%)	11/NR	NR 83% (77% to 88%) 90% (87% to 93%)
	HBV	4/NR	NR 84% (67% to 93%) 78%	6/NR	NR 80% (61% to 91%) 86% (82% to 94%)

		<b>Significant Fibrosis (i.e., Metavir Stages F2 to F4)</b>		<b>Cirrhosis (i.e., Metavir Stage F4)</b>	
			(68% to 85%)		
Tsochatzis et al(2014) <sup>68,</sup>	HCV	37/NR	0.87 (0.83 to 0.90) 79% (74% to 84%) 83% (77% to 88%)	36/NR	0.96 (0.94 to 0.97) 89% (84% to 92%) 91% (89% to 93%)
	HBV	13/NR	0.83 (0.76 to 0.90) 71% (62% to 78%) 84% (74% to 91%)	13/NR	0.92 (0.89 to 0.96) 86% (79% to 91%) 85% (78% to 89%)
	NAFLD			4/NR	0.96 (0.94 to 0.99) 96% (83% to 99%) 89% (85% to 92%)
	ALD			6/NR	0.90 (0.87 to 0.94) 86% (76% to 92%) 83% (74% to 89%)
Xu et al(2015) <sup>76,</sup>	HBV	14/2318	0.82 (0.78 to 0.86) NR NR	18/2996	0.91 (0.89 to 0.93) NR NR
Xue-Ying (2020) <sup>69,</sup>	HBV	29/5035	0.83 (0.80 to 0.86) 72% (68% to 76%) 82% (77% to 86%)	NR/NR	NR NR NR

ALD: alcoholic liver disease; AUROC: area under the receiver operating characteristic curve; CI: confidence interval; HBV: hepatitis B virus; HCV: hepatitis C virus; HIV: human immunodeficiency virus; NAFLD: nonalcoholic fatty liver disease; NR: not reported.

### Clinically Useful

A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, more effective therapy, or avoid unnecessary therapy or testing.

### **Direct Evidence**

Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from RCTs.

There are currently no published studies that directly demonstrate the effect of transient elastography (e.g., FibroScan) on patient outcomes.

FibroScan is used extensively in practice to make management decisions. In addition, FibroScan was used as an alternative to biopsy to diagnose fibrosis or cirrhosis to establish trial eligibility in several trials (ION-1,-3; VALENCE; ASTRAL-2, -3, -4) that confirmed the efficacy of HCV treatments.<sup>13,14,15,16,17,18</sup> For example, in the VALENCE trial, cirrhosis could be defined by liver biopsy or a confirmatory FibroTest or FibroScan result at 12.5 kPa or greater. In VALENCE, FibroScan was used to determine cirrhosis in 74% of the participants. In a retrospective, multicenter analysis of 7256 chronic HCV patients by Abdel Alem et al (2019), both transient elastography and FIB-4 were found to be predictors of treatment failure to sofosbuvir-based treatment regimens with an NPV of 95%.<sup>77</sup>

### **Chain of Evidence**

Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility.

### **Section Summary: Transient Elastography (FibroScan)**

For individuals who have chronic liver disease who receive transient elastography (e.g., FibroScan), the evidence includes many systematic reviews of more than 50 observational studies (>10,000 patients). Transient elastography has been studied in populations with viral hepatitis, NAFLD, and ALD. There are varying cutoffs for positivity. Failures of the test are not uncommon, particularly for those with high body mass index, but these failures often went undetected in analyses of the validation studies. Given these limitations and the imperfect reference standard, it can be difficult to interpret performance characteristics. However, for the purposes of deciding whether a patient has severe fibrosis or cirrhosis, the FibroScan results provide data sufficiently useful to determine therapy. In fact, FibroScan has been used as an alternative to biopsy to establish eligibility regarding the presence of fibrosis or cirrhosis in the participants of several RCTs. These trials showed the efficacy of HCV treatments, which in turn demonstrated that the test can identify patients who would benefit from therapy.

## **NONINVASIVE IMAGING: MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING**

### **Clinical Context and Test Purpose**

The purpose of noninvasive testing in individuals with chronic liver disease is to detect liver fibrosis so that individuals can avoid the potential adverse events of an invasive liver biopsy and receive appropriate treatment. The degree of liver fibrosis is an important factor in determining the appropriate approach for managing individuals with liver disease (e.g., hepatitis, ALD, NAFLD).

The following PICO was used to select literature to inform this review.

**Populations**

The relevant population of interest is individuals with chronic liver disease.

**Interventions**

The test being considered is multiparametric MRI (e.g., LiverMultiScan).

**Comparators**

The following tests and practices are currently being used to diagnose chronic liver disease: liver biopsy, other noninvasive radiologic methods, and multianalyte serum assays.

**Outcomes**

The general outcomes of interest are test validity, morbid events, and treatment-related morbidity. Follow-up over months to years is of interest to the relevant outcomes.

**Study Selection Criteria**

For the evaluation of the clinical validity of the tests within this review, studies that meet the following eligibility criteria were considered:

- Reported on the accuracy of the marketed version of the technology (including any algorithms used to calculate scores).
- Included a suitable reference standard (describe the reference standard).
- Patient/sample clinical characteristics were described.
- Patient/sample selection criteria were described.

**Clinically Valid**

A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

**Review of Evidence**

Azizi et al (2024) published a systematic review comparing the diagnostic accuracy of MRI proton density fat fraction with liver biopsy.<sup>78</sup> Tables 7 and 8 summarize study characteristics and results, respectively. Authors concluded that MRI Proton Density Fat Fraction has high diagnostic accuracy, though its accuracy slightly declines as the severity of hepatic steatosis increases.

**Table 7. Magnetic Resonance Imaging Systematic Review Characteristics**

Study	Dates	Studies	N (Range)	Population	Index tests	Reference Standard
Azizi et al (2024) <sup>78</sup> ,	Until January 2024	22	2844 (19 to 497)	Patients with MASLD and hepatic steatosis	MRI-PDFF	Histology

Abbreviations. MASLD: metabolic dysfunction-associated steatotic liver disease; MRI:magnetic resonance imaging; PDFF:proton density fat-fraction.

**Table 8. Magnetic Resonance Imaging Systematic Review Results**

Index Test	Steatosis		
	AUC	Sensitivity	Specificity
Azizi et al (2024) <sup>78,</sup>			
	Grade ≥1	Grade ≥2	Grade 3
Total studies (n)	17 (2454)	16 (1726)	12 (1469)
Index Test Threshold	5.7	NR	NR
MRI-PDFF	0.97 0.93 0.93	0.91 0.79 0.90	0.91 0.76 0.89

Abbreviations: AUC:area under the curve; MRI:magnetic resonance imaging; NR: not reported; PDFF:proton density fat-fraction.

Tables 9 and 10 summarize studies that have evaluated the diagnostic accuracy of multiparametric MRI, which incorporates assessment of proton density fat-fraction, T<sub>2</sub><sup>\*</sup>, and T<sub>1</sub> mapping to characterize liver fat, iron, fibrosis, and inflammation. Generally, technical failures were less common with MRI than transient elastography.<sup>79,80,81,</sup>

**Table 9. Characteristics of Studies Assessing the Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging**

Study	Population	Design	Index Test(s)	Reference Standard	Timing of Reference and Index Tests
Beyer et al (2021) <sup>79,</sup>	N=580 patients with suspected NAFLD/NASH	Retrospective evaluation of patients from 2 clinical trials	MRI PDFF (LMS-IDEAL)* CAP (FibroScan)	Liver biopsy	Not reported
Imajo et al (2021) <sup>80,</sup>	N=145 patients with suspected NASH	Prospective, observational	MRI liver fat* MRI cT <sub>1</sub> measurements* MRI cT <sub>1</sub> + PDFF* MRE VCTE-LSM (FibroScan) CAP (FibroScan) 2D-SWE	Liver biopsy	All performed at first clinical visit
McDonald et al (2018) <sup>81,</sup>	N=149 patients with known or suspected liver disease	Prospective, validation cohort	MRI cT <sub>1</sub> * ELF test TE (FibroScan)	Liver biopsy	Liver biopsy performed within 2 weeks of noninvasive assessments

\*Measurements obtained with LiverMultiscan protocol.

2D-SWE: 2-dimensional shear-wave elastography; CAP: controlled attenuation parameter; ELF: Enhanced Liver Fibrosis; LMS-IDEAL: LiverMultiScan-Iterative Decomposition of water and fat with Echo Asymmetry and Least-

squares estimation; MRE: magnetic resonance elastography; MRI: magnetic resonance imaging; NAFLD: non-alcoholic fatty liver disease; NASH: non-alcoholic steatohepatitis; PDFF: proton density fat-fraction; TE: transient elastography; VCTE-LSM: vibration-controlled transient elastography-liver stiffness measure.

**Table 10. Results of Studies Assessing the Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging**

Study	Population	Significant Fibrosis		Steatosis			Advanced NASH (NAS ≥4 and ≥F2)		
		Test	AUROC (95% CI) Sensitivity Specificity	Test	AUROC (95% CI) Sensitivity Specificity		Test	AUROC (95% CI) Sensitivity Specificity	
					Grade ≥1	Grade ≥2	Grade ≥3		
Beyer et al (2021) <sup>79</sup> ,	Suspected NAFLD/NASH	-	-	MRI PDFF (LMS-IDEAL)*	1.0 (0.99 to 1.00) 99% 100%	0.77 (0.73 to 0.82) 72% 72%	0.81 (0.76 to 0.87) 68% 81%	-	-
		-	-	CAP (FibroScan)	0.95 (0.91 to 0.99) 89% 100%	0.60 (0.55 to 0.65) 78% 41%	0.63 (0.57 to 0.70) 61% 59%	-	-
			Stage ≥2						
Imajo et al (2021) <sup>80</sup> ,	Suspected NASH	MRE	0.92 (0.87 to 0.97) NR NR	MRI liver fat*	0.92 (0.87 to 0.98) NR NR	0.86 (0.80 to 0.93) NR NR	-	MRI cT <sub>1</sub> *	0.74 (0.66 to 0.82) NR NR
		VCTE-LSM	0.88 (0.81 to 0.95) NR NR	CAP (FibroScan)	0.75 (0.58 to 0.92) NR NR	0.68 (0.59 to 0.78) NR NR	-	MRI liver fat*	0.71 (0.63 to 0.80) NR NR
		2D-SWE	0.87 (0.76 to 0.99) NR NR					MRE	0.66 (0.57 to 0.75) NR NR

		Significant Fibrosis		Steatosis				Advanced NASH (NAS ≥4 and ≥F2)	
		MRI cT <sub>1</sub> *	0.62 (0.49 to 0.74) NR NR					VCTE-LSM	0.64 (0.54 to 0.74) NR NR
			Stage ≥3	Stage ≥5					
McDonald et al (2018) <sup>81</sup> ,	Known or suspected liver disease (unselected)	MRI cT <sub>1</sub> *	0.72 (0.63 to 0.80) 88% 51%	0.72 (0.64 to 0.81) 71% 64%					
		ELF test	0.70 (0.61 to 0.78) 49% 77%	0.68 (0.57 to 0.79) 19% 91%					
		TE	0.84 (0.76 to 0.91) NR NR	0.86 (0.79 to 0.93) NR NR					

\*Measurements obtained with LiverMultiscan protocol.  
 2D-SWE: 2-dimensional shear-wave elastography; AUROC: area under the receiver operating characteristic curve; CAP: controlled attenuation parameter; CI: confidence interval; ELF: Enhanced Liver Fibrosis; LMS-IDEAL: LiverMultiScan-Iterative Decomposition of water and fat with Echo Asymmetry and Least-squares estimation; MRE: magnetic resonance elastography; MRI: magnetic resonance imaging; NAFLD: non-alcoholic fatty liver disease; NASH: non-alcoholic steatohepatitis; NR: not reported; PDFF: proton density fat-fraction; TE: transient elastography; VCTE-LSM: vibration-controlled transient elastography-liver stiffness measure.

Jayaswal et al (2020) compared the prognostic value of MRI cT1 measurements, transient elastography, and multianalyte serum assays in a cohort of 197 patients with compensated chronic liver disease.<sup>82</sup> Patients who were referred for a clinically indicated liver biopsy, or with a known diagnosis of liver cirrhosis, were eligible. At baseline, patients underwent multiparametric MRI scans, transient elastography, and blood tests. Additionally, all patients received a liver biopsy and had their fibrosis rated on the Ishak scale; results of the biopsies informed clinical care. The most common underlying disease states were NAFLD (n=85, 43%), viral hepatitis (n=50, 25%), and ALD (n=22, 11%). The primary endpoint was a composite of ascites, variceal bleeding, hepatic encephalopathy, hepatocellular carcinoma, liver transplantation and mortality. Binary cutoff values were predefined. Patients were followed for a median of 43 months. Over this period, 14 new clinical events were recorded, including 11

deaths. The prognostic value of the noninvasive testing is summarized in Table 11. Technical failures were also reported (e.g., poor quality scan); reliable measurements were obtained in 182 of 197 (92%) patients for multiparametric MRI and in 121 of 160 (76%) patients for transient elastography (transient elastography was additionally not attempted in 37 patients). The study was limited by having variable follow-up periods and the effect of patients being censored at different time points was not taken into account, so sensitivities, specificities, PPVs, and NPVs should be interpreted cautiously. The CI for the survival analysis was wide likely due to the relatively small number of new clinical events observed.

**Table 11. Survival Analysis and Performance in Identifying Development of a New Clinical Event<sup>a</sup>**

Test, Binary Cutoff	Cox Regression Analysis, HR (95% CI)	Sensitivity	Specificity	Positive Predictive Value	Negative Predictive Value
Liver cT <sub>1</sub> >825 ms	9.91 (1.287 to 76.24)	92.3	47.3	11.9	98.8
Transient elastography >8 kPa	7.79 (0.974 to 62.3)	88.9	51.8	12.9	98.3
FIB-4 >1.45	4.11 (0.91 to 18.56)	84.6	47.7	10.9	97.6
APRI >1	2.645 (0.886 to 7.9)	46.2	79.2	14.3	95.1
AST/ALT >1	6.093 (1.673 to 22.19)	76.9	65.6	14.3	97.4
Ishak >F4 (liver biopsy)	12.64 (2.8 to 57.08)	84.6	73.9	20.4	98.4

<sup>a</sup>Composite of ascites, variceal bleeding, hepatic encephalopathy, HCC, liver transplantation, and mortality  
 ALT: alanine aminotransferase; APRI: AST-to-platelet ratio; AST: aspartate aminotransferase; CI: confidence interval; FIB-4: fibrosis-4 index; HR: hazard ratio; kPa: kilopascal.

Pavlidis et al (2016) evaluated whether data obtained from multiparametric MRI was predictive of all-cause mortality and liver-related clinical events.<sup>83</sup> Patients who were referred for a clinically indicated liver biopsy, or with a diagnosis of liver cirrhosis on MRI scan, were eligible. Liver-related clinical events were defined as liver-related death, hepatocellular carcinoma, and new hepatic decompensation (i.e., clinically evident ascites, variceal bleeding, and hepatic encephalopathy). Patients received multiparametric MRI and liver cT<sub>1</sub> values were mapped into a Liver Inflammation and Fibrosis (LIF) score. One hundred twenty three patients were recruited to the study; 6 were excluded due to claustrophobia or incomplete MRI data. Of the 117 patients who had complete MRI data, follow-up data were available for 112; the study reported outcomes on these 112 patients. The most common underlying disease states were NAFLD (35%), viral hepatitis (30%), and ALD (10%). Over a median follow-up time of 27 months, 10 patients had a liver-related clinical event and 6 patients died. No patients who had a LIF <2 (no or mild liver disease) developed a clinical event. Ten of 56 (18%) patients with a LIF ≥2 (moderate or severe liver disease) experienced a clinical event. A study limitation is the use



of LIF scores, which are no longer used in clinical practice. The authors further described the study as a small proof of principle study.

### **Clinically Useful**

A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, more effective therapy, or avoid unnecessary therapy or testing.

### **Direct Evidence**

Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from RCTs. The primary benefit of multiparametric MRI for chronic liver disease is the ability to avoid liver biopsy in patients without significant fibrosis. There are currently no such published studies to demonstrate the effect on patient outcomes.

Multiparametric MRI has been used as an alternative to biopsy for measuring fibrosis or cirrhosis in clinical trials. Phase 2 clinical trials have used multiparametric MRI to measure therapeutic efficacy of an investigational treatments for NASH<sup>84</sup>, and NAFLD.<sup>85</sup>

The utility of multiparametric MRI to provide clinically useful information on the presence and extent of liver fibrosis and inflammation has been evaluated in smaller prospective studies. Specifically, it has been evaluated in the setting of biochemical remission in liver diseases where noninvasive testing for continued disease activity could further aid in direct management of patients as a prognostic marker of future liver-related complications. Quantitative multiparametric MRI has been used to measure disease burden after treatment in patients with chronic HCV<sup>86</sup>, and autoimmune hepatitis.<sup>87,88,89,90</sup>

Currently, there is not evidence that demonstrates that the use of the test for response to therapy impacts decision making and that these changes in management decisions lead to improved outcomes.

### **Chain of Evidence**

Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility.

### **Section Summary: Multiparametric Magnetic Resonance Imaging**

For individuals who have chronic liver disease who receive multiparametric MRI, the evidence includes several prospective and retrospective observational studies. Multiparametric MRI (e.g., LiverMultiScan) has been studied in mixed populations, including NAFLD, viral hepatitis, and ALD. Quantitative MRI provides various measures assessing both liver fat content and fibrosis and inflammation. Various cutoffs have been utilized for positivity. Generally, multiparametric MRI performed similarly to transient elastography, and fewer technical failures of multiparametric MRI were reported. Given these limitations and the imperfect reference standard, it can be difficult to interpret performance characteristics. The prognostic ability of quantitative MRI to predict liver-related clinical events has been evaluated in 2 studies; both reported positive correlations with wide CIs. Larger cohorts with a longer follow-up time would be useful to further derive the prognostic ability. Additionally, multiparametric MRI has been

used to measure the presence of fibrosis or cirrhosis in the patients who have achieved biochemical remission after treatment in small prospective studies.

## **OTHER NONINVASIVE IMAGING**

### **Clinical Context and Test Purpose**

The purpose of noninvasive testing in individuals with chronic liver disease is to detect liver fibrosis so that individuals can avoid the potential adverse events of an invasive liver biopsy and receive appropriate treatment. The degree of liver fibrosis is an important factor in determining the appropriate approach for managing individuals with liver disease (e.g., hepatitis, ALD, NAFLD).

The following PICO was used to select literature to inform this review.

### ***Populations***

The relevant population of interest is individuals with chronic liver disease.

### ***Interventions***

The tests being considered are other noninvasive imaging, including magnetic resonance elastography (MRE), ARFI (e.g., Acuson S2000), and real-time tissue elastography (RTE; e.g., HI VISION Preirus).

### ***Comparators***

The following tests and practices are currently being used to diagnose chronic liver disease: liver biopsy, other noninvasive radiologic methods, and multianalyte serum assays.

### ***Outcomes***

The general outcomes of interest are test validity, morbid events, and treatment-related morbidity. Follow-up over months to years is of interest to the relevant outcomes.

### **Study Selection Criteria**

For the evaluation of the clinical validity of the tests within this review, studies that meet the following eligibility criteria were considered:

- Reported on the accuracy of the marketed version of the technology (including any algorithms used to calculate scores).
- Included a suitable reference standard (describe the reference standard).
- Patient/sample clinical characteristics were described.
- Patient/sample selection criteria were described.

## **ACOUSTIC RADIATION FORCE IMPULSE IMAGING**

### **Clinically Valid**

A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

**Review of Evidence**

Tables 12 and 13 summarize the characteristics and results of systematic reviews that have assessed the diagnostic accuracy of ARFI imaging.

**Table 12. Characteristics of Systematic Reviews Assessing Acoustic Radiation Force Impulse Imaging**

Study	Dates	Studies	N	Population
Bota et al (2013) <sup>56</sup> ,	To May 2012	6	518	Chronic hepatitis
Crossan et al (2015) <sup>6</sup> ,	1998 to Apr 2012	4	NR	HCV
Guo et al (2015) <sup>91</sup> ,	To Jun 2013	15	2128	Multiple diseases
Hu et al (2017) <sup>92</sup> ,	To Jul 2014	7	723	NAFLD
Lin et al (2020) <sup>93</sup> ,	To Apr 2019	29	NR	Non-viral liver disease
Jiang et al (2018) <sup>72</sup> ,	To Dec 2017	9	982	NAFLD
Liu et al (2015) <sup>94</sup> ,	To Apr 2016	23	2691	Chronic HBV or HCV
Nierhoff et al (2013) <sup>95</sup> ,	2007 to Feb 2012	36	3951	Multiple diseases

HBV: hepatitis B virus; HCV: hepatitis C virus; NAFLD: nonalcoholic fatty liver disease; NR: not reported.

**Table 13. Results of Systematic Reviews Assessing the Diagnostic Accuracy of Acoustic Radiation Force Impulse Imaging**

Study	Population	Significant Fibrosis (i.e., Metavir Stages F2 to F4)		Cirrhosis (i.e., Metavir Stage F4)	
		Studies/ Sample Size	AUROC (95% CI) Sensitivity (95% CI) Specificity (95% CI)	Studies/ Sample Size	AUROC (95% CI) Sensitivity (95% CI) Specificity (95% CI)
Bota et al (2013) <sup>56</sup> ,	Chronic hepatitis	6/518	0.88 (0.83 to 0.93) NR NR		0.92 (0.87 to 0.98) NR NR
Crossan et al (2015) <sup>6</sup> ,	HCV	4/NR	NR 85% (69% to 94%) 89% (72% to 97%)		
Guo et al (2015) <sup>91</sup> ,	Multiple diseases	13/NR	NR 76% (73% to 78%) 80% (77% to 83%)	14/NR	NR 88% (84% to 91%) 80% (81% to 84%)
Hu et al (2017) <sup>92</sup> ,	HBV, HCV	15/NR	88% (85% to 91%) 75% (69% to 78%) 85% (81% to 89%)		
Jiang et al (2018) <sup>72</sup> ,	NAFLD	6/NR	0.86 (0.83 to 0.89) 70% (59% to 79%) 84% (79% to 88%)	7/NR	0.95 (0.93 to 0.97) 89% (60% to 98%) 91% (82% to 95%)

		Significant Fibrosis (i.e., Metavir Stages F2 to F4)		Cirrhosis (i.e., Metavir Stage F4)	
Liu et al (2015) <sup>94</sup> ,	NAFLD	7/723	NR 80% (76% to 84%) 85% (81% to 89%)		
Lin et al (2020) <sup>93</sup> ,	Non-viral liver disease	23/NR	0.87 (0.83 to 0.89) 79% (73% to 83%) 81% (75% to 86%)	14/NR	0.94 (0.92 to 0.96) 89% (79% to 95%) 89% (85% to 92%)
Nierhoff et al (2013) <sup>95</sup> ,	Multiple diseases	26/NR	0.83 (0.80 to 0.86) NR NR	27/NR	0.91 (0.89 to 0.93) NR NR

AUROC: area under the receiver operating characteristic curve; CI: confidence interval; HBV: hepatitis B virus; HCV: hepatitis C virus; NAFLD: nonalcoholic fatty liver disease; NR: not reported.

The previously introduced 5-year observational study by Kluppel et al (2023) compared the prognostic value of ARFI elastography, the FIB-4 score, and liver biopsy.<sup>51</sup> AFRI was significantly better than FIB-4 at predicting liver-related death within 5 years (p=.02), but it did not differ significantly from biopsy (p=.83). For predicting liver decompensation or variceal bleeding, AFRI outperformed both biopsy (p=.02) and FIB-4 (p=.003). However, there was no significant difference between AFRI and biopsy (p=.33) or FIB-4 (p=.14) in predicting hepatocellular carcinoma.

### Clinically Useful

A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, more effective therapy, or avoid unnecessary therapy or testing.

### Direct Evidence

Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from RCTs.

There are currently no published studies that directly demonstrate the effect of ARFI imaging on patient outcomes.

### Chain of Evidence

Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility.

Because the clinical validity of ARFI imaging has not been established, a chain of evidence supporting the clinical utility of this test for this population cannot be constructed.

## MAGNETIC RESONANCE ELASTOGRAPHY

### Clinically Valid

A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

### Review of Evidence

Tables 14 and 15 summarize the characteristics and results of systematic reviews that have assessed the diagnostic accuracy of MRE. MRE has been studied primarily in hepatitis and NAFLD.

**Table 14. Characteristics of Systematic Reviews Assessing Magnetic Resonance Elastography**

Study	Dates	Studies	N	Population
Crossan et al (2015) <sup>6</sup> ,	1998 to Apr 2012	3	NR	Chronic liver disease
Guo et al (2015) <sup>91</sup> ,	To Jun 2013	11	982	Multiple diseases
Singh et al (2015) <sup>96</sup> ,	2003 to Sep 2013	12	697	Chronic liver disease
Singh et al (2016) <sup>97</sup> ,	To Oct 2014	9	232	NAFLD
Xiao et al (2017) <sup>98</sup> ,	To 2016	5	628	NAFLD

NAFLD: nonalcoholic fatty liver disease; NR: not reported.

**Table 15. Results of Systematic Reviews Assessing the Diagnostic Accuracy of Magnetic Resonance Elastography**

Study	Population	Significant Fibrosis (i.e., Stages F2 to F4)		Cirrhosis (i.e., Stage F4)	
		Studies/ Sample Size	AUROC (95% CI) Sensitivity (95% CI) Specificity (95% CI)	Studies/ Sample Size	AUROC (95% CI) Sensitivity (95% CI) Specificity (95% CI)
Crossan et al (2015) <sup>6</sup> ,	Chronic liver disease	3/NR	NR 94% (13% to 100%) 92% (72% to 98%)		
Guo et al (2015) <sup>91</sup> ,	Multiple diseases	9/NR	NR 87% (84% to 90%) 94% (91% to 97%)		NR 93% (88% to 96%) 91% (88% to 93%)
Singh et al (2015) <sup>96</sup> ,	Chronic hepatitis	12/697	0.84 (0.76 to 0.92) 73% (NR) 79% (NR)	12/697	0.92 (0.90 to 0.94) 91% (NR) 81% (NR)
Singh et al (2016) <sup>97</sup> ,	NAFLD	9/232	0.87 (0.82 to 0.93) 79% (76% to 90%) 81% (72% to 91%)	9/232	0.91 (0.76 to 0.95) 88% (82% to 100%) 87% (77% to 97%)
Xiao et al (2017) <sup>98</sup> ,	NAFLD	3/384	0.88 (0.83 to 0.92) 73.2% (65.7% to 87.3%) 90.7% (85.0% to 95.7%)	3/384	0.92 (0.80 to 1.00) 86.6% (80.0% to 90.9%) 93.4% (91.4% to 94.5%)

AUROC: area under the receiver operating characteristic curve; CI: confidence interval; NAFLD: nonalcoholic fatty liver disease; NR: not reported.

### **Clinically Useful**

A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, more effective therapy, or avoid unnecessary therapy or testing.

### **Direct Evidence**

Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from RCTs.

There are currently no published studies that directly demonstrate the effect of MRE on patient outcomes.

### **Chain of Evidence**

Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility.

Because the clinical validity of MRE has not been established, a chain of evidence supporting the clinical utility of this test for this population cannot be constructed.

### **Real-Time Tissue Elastography (HI VISION 15 Preirus)**

#### **Clinically Valid**

A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

### **Review of Evidence**

Kobayashi et al (2015) published the results of a meta-analysis assessing RTE for staging liver fibrosis.<sup>99</sup> The authors selected 15 studies (N=1626) published through December 2013, including patients with multiple liver diseases and healthy adults. A bivariate random-effects model was used to estimate summary sensitivity and specificity. The summary AUROC, sensitivity, and specificity were 0.69, 79% (95% CI, 75% to 83%), and 76% (95% CI, 68% to 82%) for detection of significant fibrosis (stage  $\geq$ F2), and 0.72, 74% (95% CI, 63% to 82%), and 84% (95% CI, 79% to 88%) for detection of cirrhosis, respectively. Reviewers found evidence of heterogeneity due to differences in study populations, scoring methods, and cutoffs for positivity. They also found evidence of publication bias based on funnel plot asymmetry.

Hong et al (2014) reported on the results of a meta-analysis evaluating RTE for staging fibrosis in multiple diseases.<sup>100</sup> Thirteen studies (N=1,347) published between April 2000 and April 2014 that used a liver biopsy or transient elastography as the reference standard were included. Different quantitative methods were used to measure liver stiffness in the included studies: Liver Fibrosis Index (LFI), Elasticity Index, elastic ratio 1 (ER1), and elastic ratio 2. For predicting significant fibrosis (stage  $\geq$ F2), the pooled sensitivities for LFI and ER1 were 78% (95% CI, 70% to 84%) and 86% (95% CI, 80% to 90%), respectively. The specificities were 63% (95% CI, 46% to 78%) and 89% (95% CI, 83% to 94%) and the AUROCs were 0.79 (95% CI, 0.75 to 0.82) and 0.94 (95% CI, 0.92 to 0.96), respectively. For predicting cirrhosis (stage F4), the pooled sensitivities of LFI, ER1, and elastic ratio 2 were 79% (95% CI, 61% to

91%), 96% (95% CI, 87% to 99%), and 79% (95% CI, 61% to 91%), respectively. The specificities were 88% (95% CI, 81% to 93%) for LFI, 89% (95% CI, 83% to 93%) for ER1, and 88% (95% CI, 81% to 93%) for elastic ratio 2, and the AUROCs were 0.85 (95% CI, 0.81 to 0.87), 0.93 (95% CI, 0.94 to 0.98), and 0.92 (95% CI, not reported), respectively. Pooled estimates for Elasticity Index were not performed due to insufficient data.

### **Clinically Useful**

A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, more effective therapy, or avoid unnecessary therapy or testing.

### **Direct Evidence**

Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from RCTs.

There are currently no published studies that directly demonstrate the effect of RTE on patient outcomes.

### **Chain of Evidence**

Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility.

Because the clinical validity of RTE has not been established, a chain of evidence supporting the clinical utility of this test for this population cannot be constructed.

### **Section Summary: Noninvasive Radiological Methods Other Than Transient Elastography**

The use of ARFI imaging has been evaluated in viral hepatitis and NAFLD. Moreover, many have noted that ARFI imaging has potential advantages over FibroScan. ARFI can be implemented on a standard ultrasound machine, may be more applicable for assessing complications such as ascites, and may be more applicable in obese patients. ARFI imaging appears to have similar diagnostic accuracy to FibroScan, but there are fewer data available on performance characteristics. Validation studies have used varying cutoffs for positivity. MRE has a high success rate and is highly reproducible. The diagnostic accuracy also appears to be high. In particular, MRE has high diagnostic accuracy for the detection of fibrosis in NAFLD, independent of body mass index and degree of inflammation. However, further validation is needed to determine standard cutoffs and confirm performance characteristics because CI for estimates are wide. MRE is also not widely available. RTE has been evaluated in multiple diseases with varying scoring methods and cutoffs. Although data are limited, the accuracy of RTE appears to be similar to FibroScan for the evaluation of significant liver fibrosis, but less accurate for the evaluation of cirrhosis. However, there was evidence of publication bias in the systematic review and the diagnostic accuracy may be overestimated.

For individuals who have chronic liver disease who receive noninvasive radiologic methods other than transient elastography for liver fibrosis measurement, the evidence includes systematic reviews of observational studies and a comparative study with 5-year follow up. Other

radiologic methods (e.g., MRE, RTE, ARFI) may have similar performance for detecting significant fibrosis or cirrhosis. In the comparative study, ARFI elastography was found to be at least as effective as liver histology in predicting liver-related survival, and was superior to both histology and the FIB-4 score in predicting certain liver-related complications. Studies have frequently included varying cutoffs not prespecified or validated.

Given these limitations and the imperfect reference standard, it is difficult to interpret performance characteristics. There is no direct evidence that other noninvasive radiologic methods improve health outcomes; further, it is not possible to construct a chain of evidence for clinical utility due to the lack of sufficient evidence on clinical validity.

### **Supplemental Information**

The purpose of the following information is to provide reference material. Inclusion does not imply endorsement or alignment with the evidence review conclusions.

### **Clinical Input From Physician Specialty Societies and Academic Medical Centers**

While the various physician specialty societies and academic medical centers may collaborate with and make recommendations, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

### **2015 Input**

In response to requests, input was received from 3 physician specialty societies and 3 academic medical centers while this document was under review in 2015. Most reviewers considered noninvasive techniques for the evaluation and monitoring of chronic liver disease to be investigational, both individually and in combination.

### **Practice Guidelines and Position Statements**

Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

## **NONALCOHOLIC FATTY LIVER DISEASE**

### **American Gastroenterological Association et al**

In 2018, the practice guidelines on the diagnosis and management of nonalcoholic fatty liver disease (NAFLD), developed by the American Gastroenterological Association (AGA), the American Association for the Study of Liver Diseases (AASLD), and the American College of Gastroenterology, stated that "NFS [NAFLD fibrosis score] or FIB-4 [Fibrosis-4] index are clinically useful tools for identifying NAFLD patients with a higher likelihood of having bridging fibrosis (stage 3) or cirrhosis (stage 4)."<sup>101</sup> This guideline also cited vibration-controlled transient elastography (VCTE) and magnetic resonance elastography (MRE) as "clinically useful tools for identifying advanced fibrosis in patients with NAFLD."



A 2022 consensus-based clinical care pathway was published by the AGA on risk stratification and management of NAFLD, including some recommendations regarding the use of non-invasive testing for individuals with chronic liver disease<sup>102</sup>. Among individuals with increased risk of NAFLD or nonalcoholic steatohepatitis (NASH)-related fibrosis (i.e., individuals with type-2 diabetes,  $\geq 2$  metabolic risk factors, or an incidental finding of hepatic steatosis or elevated aminotransferases), assessment with a nonproprietary fibrosis scoring system such as FIB-4 is recommended, although aspartate transaminase to platelet ratio index can be used in lieu of FIB-4 scoring. Depending on the fibrosis score, imaging-based testing for liver stiffness may be warranted with transient elastography (FibroScan), although bidimensional shear wave elastography or point shear wave elastography are also imaging options included in the clinical care pathway.

In 2023, the AGA published an expert review on the role of noninvasive tests [NITs] in the evaluation and management of NAFLD.<sup>103</sup> The following practice advice statements were made.

- "A Fibrosis 4 Index score [FIB-4]  $< 1.3$  is associated with strong negative predictive value for advanced hepatic fibrosis and may be useful for exclusion of advanced hepatic fibrosis in patients with NAFLD
- A combination of 2 or more NITs combining serum biomarkers and/or imaging-based biomarkers is preferred for staging and risk stratification of patients with NAFLD whose Fibrosis 4 Index score [FIB-4] is  $> 1.3$
- Use of NITs in accordance with manufacturer's specifications can minimize risk of discordant results and adverse events
- NITs should be interpreted with context and consideration of pertinent clinical data...to optimize positive predictive value in the identification of patients with advanced fibrosis
- Liver biopsy should be considered for patients with NIT results that are indeterminate or discordant; conflict with other clinical, laboratory, or radiologic findings; or when alternative etiologies for liver disease are suspected
- Serial longitudinal monitoring using NITs for assessment of disease progression or regression may inform clinical management
- Patients with NAFLD and NITs results suggestive of advanced fibrosis or cirrhosis should be considered for surveillance of liver complications...Patients with NAFLD and NITs suggestive of advanced hepatic fibrosis should be monitored with serial liver stiffness measurement; vibration controlled transient elastography; or magnetic resonance elastography, given its correlation with clinically significant portal hypertension and clinical decompensation."

### **American Association for the Study of Liver Diseases**

A 2023 updated practice guidance focused on the clinical assessment and management NAFLD and hepatic steatosis issued by the AASLD included the following guidance statements on the use of noninvasive techniques for diagnosis and management of NAFLD and hepatic steatosis.<sup>104</sup>

- All patients with hepatic steatosis or clinically suspected NAFLD based on the presence of obesity and metabolic risk factors should undergo primary risk assessment with FIB-4
- In patients with pre-DM [diabetes mellitus], T2DM, or 2 or more metabolic risk factors (or imaging evidence of hepatic steatosis), primary risk assessment with FIB-4 should be repeated every 1–2 years

- Although standard ultrasound can detect hepatic steatosis, it is not recommended as a tool to identify hepatic steatosis due to low sensitivity across the NAFLD spectrum
- CAP [controlled attenuation parameter] as a point-of-care technique may be used to identify steatosis. MRI-PDFF [proton density fat fraction] can additionally quantify steatosis
- If FIB-4 is  $\geq 1.3$ , VCTE, MRE, or ELF [ Enhanced Liver Fibrosis] may be used to exclude advanced fibrosis
- Improvement in ALT or reduction in liver fat content by imaging in response to an intervention can be used as a surrogate for histological improvement in disease activity

A 2024 publication from the AASLD describes the impact of new nomenclature on the AASLD practice guidance on NAFLD and hepatic steatosis described above.<sup>105</sup> Briefly, available data suggest a near complete overlap (99%) between the metabolic dysfunction-associated steatotic liver disease (MASLD)-defined population and the historical NAFLD-defined population. Therefore, all recommendations on the clinical assessment and management of NAFLD AND NASH can be applied to patients with MASLD and metabolic-dysfunction associated steatohepatitis (MASH). Additionally, data from biomarker validation studies among patients with NAFLD and NASH are applicable to patients with MASLD and MASH, respectively, until further guidance

A 2022 joint clinical practice guideline issued by the American Association of Clinical Endocrinology and AASLD included the following recommendations on the use of noninvasive techniques for diagnosis of NAFLD with clinically significant fibrosis (stage F2 to F4)<sup>106</sup>:

- Clinicians should use liver fibrosis prediction calculations to assess the risk of NAFLD with liver fibrosis. The preferred noninvasive initial test is the FIB-4 (Grade B, Level 2 evidence)
- High-risk individuals with indeterminate or high FIB-4 score for further workup with a transient elastography or enhanced liver fibrosis test, as available (Grade B, Level 2 evidence)
- Clinicians should prefer the use of transient elastography as best validated to identify advanced disease and predict liver-related outcomes. Alternative imaging approaches may be considered, including shear wave elastography (less well validated) and/or magnetic resonance elastography (most accurate but with a high cost and limited availability; best if ordered by liver specialist for selected cases) (Grade B, Level 2 evidence).

In 2024, the AASLD published 2 guidelines focused on blood-based and imaging-based noninvasive liver disease assessment (NILDA) of hepatic fibrosis and steatosis.<sup>107,108</sup> Recommendations are provided in Table 16 and include guidance for individuals with various etiologies of chronic liver disease, including hepatocellular (hepatitis C virus [HCV], HCV/HIV, hepatitis B virus [HBV], HCV/HBV, HBV/HIV, NAFLD, alcohol-associated liver disease [ALD]) and cholestatic disorders (primary sclerosing cholangitis [PSC], primary biliary cholangitis [PBC]).

**Table 16. AASLD Recommendations for Blood- and Imaging-based Noninvasive Liver Disease Assessment.**<sup>108,107,</sup>

<b><i>Blood-based</i></b>
<ul style="list-style-type: none"> <li>• In adult patients with chronic HBV and HCV undergoing fibrosis staging prior to antiviral therapy, AASLD recommends using simple blood-based NILDA such as APRI or FIB-4 as an initial test to detect significant (F2-4), advanced fibrosis (F3-4) or cirrhosis (F4) compared with no test (strong recommendation, moderate quality of evidence)</li> <li>• In adult patients with NAFLD undergoing fibrosis staging, AASLD recommends using simple blood-based NILDA tests such as FIB-4 to detect advanced fibrosis (F3-4) compared to no test (strong recommendation, moderate quality of evidence)</li> <li>• In adult patients with ALD or chronic cholestatic liver disease undergoing fibrosis staging, there is insufficient evidence to recommend using blood-based NILDA for staging</li> <li>• In patients with chronic HCV who require fibrosis staging, AASLD recommends using simple, less costly, and readily available blood-based NILDA such as FIB-4 over complex proprietary tests (strong recommendation, moderate quality of evidence)</li> <li>• In patients with NAFLD who require fibrosis staging, AASLD recommends the use of simple, less costly, and readily available blood-based NILDA tests such as FIB-4 or NAFLD fibrosis score over complex proprietary tests for the detection of advanced fibrosis (F3-4; strong recommendation, moderate quality of evidence)</li> <li>• In patients with chronic untreated HCV, AASLD suggests a sequential combination of blood-based markers may perform better than a single biomarker for F2-4 or F4 (ungraded statement)</li> <li>• In patients with NAFLD, AASLD suggests the sequential combination of blood-based NILDA may be considered for diagnosis of advanced fibrosis (F3-4) over using a single test alone (ungraded statement)</li> <li>• AASLD suggests against the use of blood-based NILDA tests to follow progression, stability, or regression in histologic stage (as determined by biopsy) in chronic liver disease (ungraded statement).</li> </ul>
<b><i>Imaging-based</i></b>
<ul style="list-style-type: none"> <li>• In adults with chronic HCV, chronic HBV, and NAFLD, AASLD recommends using imaging-based NILDA tests to detect significant fibrosis (F2-4), advanced fibrosis (F3-4), and cirrhosis (F4) (strong recommendation, moderate quality of evidence)</li> <li>• In adults with ALD or chronic cholestatic liver disease, AASLD suggests using imaging-based NILDA tests to detect advanced fibrosis (F3-4) and cirrhosis (F4) (conditional recommendation, low quality of evidence)</li> <li>• In adults with CLD, AASLD recommends utilizing either US-based elastography methods or MRE to stage fibrosis. Depending on local availability and expertise, it is reasonable to perform MRE as an investigation when concomitant cross-sectional imaging is needed or for patients in whom the accuracy of US-based elastography might be compromised (ungraded statement)</li> <li>• In adults with CLD, AASLD suggests imaging-based NILDA be incorporated into the initial fibrosis staging process because it is more accurate than blood-based NILDA (conditional recommendation, low quality of evidence)</li> <li>• In adults with CLD undergoing initial fibrosis staging, AASLD suggests combining blood-based and imaging-based NILDA, particularly for the detection of significant fibrosis (F2-4) and advanced fibrosis (F3-4) (conditional recommendation, low quality of evidence)</li> <li>• AASLD suggests against the use of imaging-based NILDA as a standalone test to assess regression or progression of liver fibrosis (ungraded statement)</li> </ul>

### ***Blood-based***

- AASLD suggests interpreting a longitudinal decrease or increase in liver stiffness within an individualized clinical context that considers the effect of NILDA modifiers and other supportive evidence of improving or worsening clinical course (ungraded statement)
- In patients with treated HBV and HCV, AASLD suggests using the LSM obtained prior to the start of antiviral therapy as the most accurate longitudinal NILDA parameter for the effect of prognostication, given the limited amount of evidence associating LSM with clinical outcomes once viral suppression or eradication is achieved (ungraded statement)
- In adults, TE-CAP has good diagnostic accuracy to grade steatosis and can be used in clinical practice (ungraded statement)
- In adults, imaging-based NILDA, specifically TE-CAP and MRI-PDFF or MRS, are superior to blood-based NILDA tests and should be used in the assessment of hepatic steatosis where available (ungraded statement)
- In the pediatric population, there is insufficient evidence to recommend a single imaging-based NILDA over another to assess liver fibrosis or steatosis (ungraded statement)
- Recognizing that liver histology is an imperfect reference standard, prior to considering a liver biopsy to assess fibrosis staging in patients with CLD, AASLD recommends using blood and imaging-based NILDA as the initial tests to detect significant (F2-4) to advanced fibrosis (F3-4) and cirrhosis (F4) (ungraded statement)

Abbreviations: AASLD: American Association for the Study of Liver Diseases; ALD: alcohol-associated liver disease; APRI: acoustic radiation force impulse; CLD: chronic liver disease; FIB-4: Fibrosis-4 Index; HBV: hepatitis B virus; HCV: hepatitis C virus; LSM: liver stiffness measurement; MRE: magnetic resonance elastography; MRI-PDFF: magnetic resonance imaging proton density fat fraction; MRS: magnetic resonance spectroscopy; NILDA: noninvasive liver disease assessment; TE-CAP: US: ultrasound;

### **National Institute for Health and Care Excellence**

In 2016, the NICE published guidance on the assessment and management of NAFLD.<sup>54</sup> The guidance did not reference elastography. The guidance recommended the enhanced liver fibrosis test to test for advanced liver fibrosis, utilizing a cutoff enhanced liver fibrosis score of 10.51.

### **American Gastroenterological Association Institute**

In 2017, the American Gastroenterological Association Institute published guidelines on the role of elastography in chronic liver disease. The guidelines indicate that, in adults with NAFLD, VCTE has superior diagnostic sensitivity and specificity for diagnosing cirrhosis when compared to the aspartate aminotransferase platelet ratio index (APRI) or FIB-4 tests (very low quality of evidence).<sup>109</sup> Moreover, the guidelines state that, in adults with NAFLD, magnetic resonance-guided elastography has little or no increased diagnostic accuracy for identifying cirrhosis compared with VCTE in patients who have cirrhosis, and has higher diagnostic accuracy than VCTE in patients who do not have cirrhosis (very low quality of evidence).

## **HEPATITIS B AND C VIRUSES**

### **American Association for the Study of Liver Diseases**

In 2024, the AASLD published 2 guidelines focused on blood-based and imaging-based NILDA of hepatic fibrosis and steatosis.<sup>107,108</sup> Recommendations regarding the use of these noninvasive assessments for patients with HBV and HCV are found in Table 16.

### **American Association for the Study of Liver Diseases and Infectious Diseases Society of America**

In 2020, the American Association for the Study of Liver Diseases and Infectious Diseases Society of America guidelines for testing, managing, and treating hepatitis C virus (HCV) recommended that, for counseling and pretreatment assessment purposes, the following should be completed:

"Evaluation for advanced fibrosis using noninvasive markers and/or elastography, and rarely liver biopsy, is recommended for all persons with HCV infection to facilitate decision making regarding HCV treatment strategy and determine the need for initiating additional measures for the management of cirrhosis (e.g., hepatocellular carcinoma screening) Rating: Class I, Level A [evidence and/or general agreement; data derived from multiple randomized trials, or meta-analyses]"<sup>110</sup>,

The guidelines noted that there are several NITs to stage the degree of fibrosis in patients with HCV. Tests included indirect serum biomarkers, direct serum biomarkers, and VCTE. The guidelines asserted that no single method is recognized to have high accuracy alone and careful interpretation of these tests is required.

A 2023 update of this guideline includes noninvasive liver markers such as HCV FibroSure, FIB-4, and FibroScan in their simplified treatment algorithm for HCV.<sup>111</sup> Specific recommendations for a preferred noninvasive testing strategy are not provided.

### **American Gastroenterological Association Institute**

In 2017, guidelines published by the American College of Gastroenterology Institute on the role of elastography in chronic liver disease indicated that, in adults with chronic hepatitis B virus and chronic HCV, VCTE has superior diagnostic performance for diagnosing cirrhosis when compared to the APRI and FIB-4 tests (moderate quality of evidence for HCV, low quality of evidence for hepatitis B virus).<sup>109</sup> In addition, the guidelines state that, in adults with HCV, magnetic resonance-guided elastography has little or no increased diagnostic accuracy for identifying cirrhosis compared with VCTE in patients who have cirrhosis, and has lower diagnostic accuracy than VCTE in patients who do not have cirrhosis (very low quality of evidence).

### **National Institute for Health and Care Excellence**

In 2017, the NICE published updated guidance on the management and treatment of patients with hepatitis B virus.<sup>112</sup> The guidance recommends offering transient elastography as the initial test in adults diagnosed with chronic hepatitis B, to inform the antiviral treatment decision (Table 17).

**Table 17. Antiviral Treatment Recommendations by Transient Elasticity Score**

<b>Transient Elasticity Score</b>	<b>Antiviral Treatment</b>
>11 kPa	Offer antiviral treatment
6 to 10 kPa	Offer liver biopsy to confirm fibrosis level prior to offering antiviral treatment
<6 kPa plus abnormal ALT	Offer liver biopsy to confirm fibrosis level prior to offering antiviral treatment
<6 kPa plus normal ALT	Do not offer antiviral treatment

ALT: alanine aminotransferase; kPa: kilopascal.

### **Chronic Liver Disease**

In 2024, the AASLD published 2 guidelines focused on blood-based and imaging-based NILDA of hepatic fibrosis and steatosis.<sup>107,108</sup> Recommendations regarding the use of these noninvasive assessments for patients with chronic liver disease, including hepatocellular (HCV, HCV/HIV, HBV, HCV/HBV, HBV/HIV, NAFLD, ALD) and cholestatic disorders (PSC, PBC) are found in Table 16.

### **American College of Radiology**

In 2020, the American College of Radiology appropriateness criteria rated ultrasound shear wave elastography as an 8 (usually appropriate) for the diagnosis of liver fibrosis in patients with chronic liver disease.<sup>113</sup> The criteria noted that high-quality data can be difficult to obtain in obese patients, and assessments of liver stiffness can be confounded by parenchyma, edema, inflammation, and cholestasis.

### **U.S. Preventive Services Task Force Recommendations**

A 2020 U.S. Preventive Services Task Force Recommendation Statement for HCV screening notes that a diagnostic evaluation for fibrosis stage or cirrhosis with a noninvasive test reduces the risk for harm compared to a liver biopsy.<sup>114</sup> This statement does not give preference to a specific noninvasive test.

### **Ongoing and Unpublished Clinical Trials**

Some currently ongoing and unpublished trials that might influence this review are listed in Table 18.

**Table 18. Summary of Key Trials**

<b>NCT No.</b>	<b>Trial Name</b>	<b>Planned Enrollment</b>	<b>Completion Date</b>
<i>Ongoing</i>			
NCT06592820	Shear Wave Elastography Registry Study (SW)	300	September 2026 (not yet recruiting)
NCT06463366	Multi-parametric Magnetic Resonance Imaging for the Precise Diagnosis and Quantitative Study of Liver Steatosis, Inflammation, and Fibrosis in Chronic Liver Disease.	100	June 2025 (recruiting)
NCT03789825	Screening for Liver Fibrosis. A Population-based Study in European Countries. The "LiverScreen" Project.	20000	Dec 2023 (unknown status )
NCT03308916 <sup>a</sup>	Screening At-risk Populations for Hepatic Fibrosis With Non-invasive Markers (SIPHON)	6500	Oct 2035 (recruiting)
NCT02037867	The Stratification of Liver Disease in the Community Using Fibrosis Biomarkers	2000	May 2033 (recruiting)
NCT04435054	Screening for NAFLD-related Advanced Fibrosis in High Risk population: Optimization of the Diabetology Pathway Referral Using Combinations of Non-invasive Biological and elastography parameters	1000	Oct 2023 (recruiting)
NCT04365855	The Olmsted NAFLD Epidemiology Study (TONES)	800	Jun 2028 (recruiting)
NCT04550481	Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study	45	Sept 2025 (recruiting)

NCT: national clinical trial.

<sup>a</sup> Denotes industry-sponsored or cosponsored trial.

## CODING

**The following codes for treatment and procedures applicable to this policy are included below for informational purposes. This may not be a comprehensive list of procedure codes applicable to this policy.**

**Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.**

**The code(s) listed below are medically necessary ONLY if the procedure is performed according to the "Policy" section of this document.**

<b>CPT/HCPCS</b>	
76391	Magnetic resonance (e.g., vibration) elastography
76981	Ultrasound, elastography; parenchyma (e.g., organ)
76982	Ultrasound, elastography; first target lesion
76983	Ultrasound, elastography; each additional target lesion (List separately in addition to code for primary procedure)
81517	Liver disease, analysis of 3 biomarkers (hyaluronic acid [HA], procollagen III amino terminal peptide [PIIINP], tissue inhibitor of metalloproteinase 1 [TIMP-1]), using immunoassays, utilizing serum, prognostic algorithm reported as a risk score and risk of liver fibrosis and liver[1]related clinical events within 5 years
81596	Infectious disease, chronic hepatitis C virus (HCV) infection, six biochemical assays (ALT, A2-macroglobulin, apolipoprotein A-1, total bilirubin, GGT, and haptoglobin) utilizing serum, prognostic algorithm reported as scores for fibrosis and necroinflammatory activity in liver
83520	Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified
83883	Nephelometry, each analyte not elsewhere specified
91200	Liver elastography, mechanically induced shear wave (e.g., vibration), without imaging, with interpretation and report
0002M	Liver disease, ten biochemical assays (ALT, A2-macroglobulin, apolipoprotein A-1, total bilirubin, GGT, haptoglobin, AST, glucose, total cholesterol and triglycerides) utilizing serum, prognostic algorithm reported as quantitative scores for fibrosis, steatosis and alcoholic steatohepatitis (ASH)
0003M	Liver disease, ten biochemical assays (ALT, A2-macroglobulin, apolipoprotein A-1, total bilirubin, GGT, haptoglobin, AST, glucose, total cholesterol and triglycerides) utilizing serum, prognostic algorithm reported as quantitative scores for fibrosis, steatosis and nonalcoholic steatohepatitis (NASH)
0166U	Liver disease, 10 biochemical assays (α2-macroglobulin, haptoglobin, apolipoprotein A1, bilirubin, GGT, ALT, AST, triglycerides, cholesterol, fasting glucose) and biometric and demographic data, utilizing serum, algorithm reported as scores for fibrosis, necroinflammatory activity, and steatosis with a summary interpretation



<b>CPT/HCPCS</b>	
0648T	Quantitative magnetic resonance for analysis of tissue composition (e.g., fat, iron, water content), including multiparametric data acquisition, data preparation and transmission, interpretation and report, obtained without diagnostic MRI examination of the same anatomy (e.g., organ, gland, tissue, target structure) during the same session
0649T	Quantitative magnetic resonance for analysis of tissue composition (e.g., fat, iron, water content), including multiparametric data acquisition, data preparation and transmission, interpretation and report, obtained with diagnostic MRI examination of the same anatomy (e.g., organ, gland, tissue, target structure) (List separately in addition to code for primary procedure)

<b>REVISIONS</b>	
09-16-2016	Policy added to the bcbsks.com web site on 08-17-2016.
01-18-2017	Updated Description section.
	Updated Rationale section.
	Updated References section.
12-20-2017	Updated Description section.
	Updated Rationale section.
	In Coding section: <ul style="list-style-type: none"> <li>▪ Added CPT code 0346T.</li> </ul>
	Updated References section.
01-01-2019	In Coding section: <ul style="list-style-type: none"> <li>▪ Added new CPT codes: 76391, 76981, 76982, 76983, 81596.</li> </ul>
02-01-2019	Policy posted 01-04-2019 with an effective date of 02-01-2019.
	Updated Description section.
	In Policy section: <ul style="list-style-type: none"> <li>▪ Added new Item A, "A single FibroSURE multianalyte assay may be considered medically necessary for the initial evaluation of patients with chronic liver disease."</li> <li>▪ In new Item B (previous Item A), removed "with algorithmic analyses" and "the evaluation or" and added "FibroSURE" to read, "FibroSURE Multianalyte assays are considered experimental / investigational for monitoring of patients with chronic liver disease."</li> <li>▪ Added new Item C, "Other multianalyte assays with algorithmic analyses are considered experimental / investigational for the initial evaluation or monitoring of patients with chronic liver disease."</li> <li>▪ In new Item D (previous Item B), removed "ARFI" and added "initial" to read, "The use of noninvasive imaging, including, but not limited to, transient elastography (e.g., FibroScan), magnetic resonance elastography, acoustic radiation force impulse imaging (e.g., Acuson S2000), or real-time tissue elastography, is considered experimental / investigational for the initial evaluation or monitoring of patients with chronic liver disease."</li> </ul>
	Updated Rationale section.
	In Coding section: <ul style="list-style-type: none"> <li>▪ Removed CPT code: 0346T (<i>deleted January 1, 2019</i>).</li> </ul>
	Updated References section.
	Updated Description section.
03-13-2019	Updated Description section.
	In Policy section:

<b>REVISIONS</b>	
	<ul style="list-style-type: none"> <li>▪ Added new Item D, "Transient elastography (FibroScan) imaging may be considered medically necessary for the initial evaluation of patients with chronic liver disease."</li> <li>▪ Added new Item E, "Transient elastography (FibroScan) imaging is considered experimental / investigational for monitoring of patients with chronic liver disease."</li> <li>▪ In Item F (previously Item D), removed "transient elastography (e.g., FibroScan)" to read, "The use of other noninvasive imaging, including, but not limited to, magnetic resonance elastography, acoustic radiation force impulse imaging (e.g., Acuson S2000), or real-time tissue elastography, is considered experimental / investigational for the initial evaluation or monitoring of patients with chronic liver disease."</li> </ul>
	Updated Rationale section.
	In Coding section: <ul style="list-style-type: none"> <li>▪ Removed CPT code: 0001M.</li> </ul>
	Updated References section.
02-25-2021	Updated Description section
	Updated Rationale section
	Updated Reference section
07-01-2021	In Coding section <ul style="list-style-type: none"> <li>▪ Added codes 0648T and 0649T (effective 07-01-21)</li> </ul>
01-04-2022	Updated Description Section
	Updated Rationale Section
	Updated Codes Section <ul style="list-style-type: none"> <li>▪ Added: 0014M, 0166U</li> <li>▪ Deleted Codes:84999</li> </ul>
	Updated References Section
12-29-2022	Updated Description Section
	Updated Policy Section <ul style="list-style-type: none"> <li>▪ Section F Added: "multiparametric magnetic resonance imaging" as a noninvasive imaging</li> </ul>
	Updated Rationale Section
	Updated Reference Section
01-05-2024	Updated Description Section
	Update Rationale Section
	Updated Coding Section <ul style="list-style-type: none"> <li>▪ Removed Deleted Code 0014M (eff. 01-01-2024)</li> <li>▪ Removed ICD-10 Diagnoses Box</li> <li>▪ Added New code 81517 (eff. 01-01-2024)</li> </ul>
	Updated References Section
12-23-2024	Updated Description Section
	Update Rationale Section
	Updated References Section

## REFERENCES

1. Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. *Hepatology*. Dec 01 2023; 78(6): 1966-1986. PMID 37363821

2. Regev A, Berho M, Jeffers LJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. *Am J Gastroenterol*. Oct 2002; 97(10): 2614-8. PMID 12385448
3. Rockey DC, Caldwell SH, Goodman ZD, et al. Liver biopsy. *Hepatology*. Mar 2009; 49(3): 1017-44. PMID 19243014
4. Mehta SH, Lau B, Afdhal NH, et al. Exceeding the limits of liver histology markers. *J Hepatol*. Jan 2009; 50(1): 36-41. PMID 19012989
5. Trikalinos TA, Balion CM. Chapter 9: options for summarizing medical test performance in the absence of a "gold standard". *J Gen Intern Med*. Jun 2012; 27 Suppl 1(Suppl 1): S67-75. PMID 22648677
6. Crossan C, Tsochatzis EA, Longworth L, et al. Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation. *Health Technol Assess*. Jan 2015; 19(9): 1-409, v-vi. PMID 25633908
7. Houot M, Ngo Y, Munteanu M, et al. Systematic review with meta-analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B. *Aliment Pharmacol Ther*. Jan 2016; 43(1): 16-29. PMID 26516104
8. Imbert-Bismut F, Ratziu V, Pieroni L, et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. *Lancet*. Apr 07 2001; 357(9262): 1069-75. PMID 11297957
9. Poynard T, McHutchison J, Manns M, et al. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. *Hepatology*. Aug 2003; 38(2): 481-92. PMID 12883493
10. Poynard T, Munteanu M, Imbert-Bismut F, et al. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. *Clin Chem*. Aug 2004; 50(8): 1344-55. PMID 15192028
11. Afdhal NH, Nunes D. Evaluation of liver fibrosis: a concise review. *Am J Gastroenterol*. Jun 2004; 99(6): 1160-74. PMID 15180741
12. Lichtiginghagen R, Bahr MJ. Noninvasive diagnosis of fibrosis in chronic liver disease. *Expert Rev Mol Diagn*. Sep 2004; 4(5): 715-26. PMID 15347264
13. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. *N Engl J Med*. Apr 17 2014; 370(16): 1483-93. PMID 24725238
14. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. *N Engl J Med*. May 15 2014; 370(20): 1889-98. PMID 24725239
15. Curry MP, O'Leary JG, Bzowej N, et al. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. *N Engl J Med*. Dec 31 2015; 373(27): 2618-28. PMID 26569658
16. Foster GR, Afdhal N, Roberts SK, et al. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. *N Engl J Med*. Dec 31 2015; 373(27): 2608-17. PMID 26575258
17. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. *N Engl J Med*. May 15 2014; 370(20): 1879-88. PMID 24720702
18. Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. *N Engl J Med*. May 22 2014; 370(21): 1993-2001. PMID 24795201

19. Naveau S, Raynard B, Ratziu V, et al. Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease. *Clin Gastroenterol Hepatol*. Feb 2005; 3(2): 167-74. PMID 15704051
20. Ratziu V, Massard J, Charlotte F, et al. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. *BMC Gastroenterol*. Feb 14 2006; 6: 6. PMID 16503961
21. Lassailly G, Caiazzo R, Hollebecque A, et al. Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity. *Eur J Gastroenterol Hepatol*. Jun 2011; 23(6): 499-506. PMID 21499110
22. Poynard T, Ratziu V, Charlotte F, et al. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholic steato hepatitis in patients with non-alcoholic fatty liver disease. *BMC Gastroenterol*. Nov 10 2006; 6: 34. PMID 17096854
23. Mohamadnejad M, Montazeri G, Fazlollahi A, et al. Noninvasive markers of liver fibrosis and inflammation in chronic hepatitis B-virus related liver disease. *Am J Gastroenterol*. Nov 2006; 101(11): 2537-45. PMID 17029616
24. Zeng MD, Lu LG, Mao YM, et al. Prediction of significant fibrosis in HBeAg-positive patients with chronic hepatitis B by a noninvasive model. *Hepatology*. Dec 2005; 42(6): 1437-45. PMID 16317674
25. Park MS, Kim BK, Cheong JY, et al. Discordance between liver biopsy and FibroTest in assessing liver fibrosis in chronic hepatitis B. *PLoS One*. 2013; 8(2): e55759. PMID 23405210
26. Salkic NN, Jovanovic P, Hauser G, et al. FibroTest/Fibrosure for significant liver fibrosis and cirrhosis in chronic hepatitis B: a meta-analysis. *Am J Gastroenterol*. Jun 2014; 109(6): 796-809. PMID 24535095
27. Xu XY, Kong H, Song RX, et al. The effectiveness of noninvasive biomarkers to predict hepatitis B-related significant fibrosis and cirrhosis: a systematic review and meta-analysis of diagnostic test accuracy. *PLoS One*. 2014; 9(6): e100182. PMID 24964038
28. Wai CT, Cheng CL, Wee A, et al. Non-invasive models for predicting histology in patients with chronic hepatitis B. *Liver Int*. Aug 2006; 26(6): 666-72. PMID 16842322
29. Patel K, Gordon SC, Jacobson I, et al. Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. *J Hepatol*. Dec 2004; 41(6): 935-42. PMID 15582126
30. Mehta P, Ploutz-Snyder R, Nandi J, et al. Diagnostic accuracy of serum hyaluronic acid, FIBROSpect II, and YKL-40 for discriminating fibrosis stages in chronic hepatitis C. *Am J Gastroenterol*. Apr 2008; 103(4): 928-36. PMID 18371145
31. Patel K, Nelson DR, Rockey DC, et al. Correlation of FIBROSpect II with histologic and morphometric evaluation of liver fibrosis in chronic hepatitis C. *Clin Gastroenterol Hepatol*. Feb 2008; 6(2): 242-7. PMID 18187364
32. Snyder N, Nguyen A, Gajula L, et al. The APRI may be enhanced by the use of the FIBROSpect II in the estimation of fibrosis in chronic hepatitis C. *Clin Chim Acta*. Jun 2007; 381(2): 119-23. PMID 17442291
33. Castellana M, Donghia R, Guerra V, et al. Fibrosis-4 Index vs Nonalcoholic Fatty Liver Disease Fibrosis Score in Identifying Advanced Fibrosis in Subjects With Nonalcoholic Fatty Liver Disease: A Meta-Analysis. *Am J Gastroenterol*. Sep 01 2021; 116(9): 1833-1841. PMID 34160377

34. Mózes FE, Lee JA, Selvaraj EA, et al. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. *Gut*. May 2022; 71(5): 1006-1019. PMID 34001645
35. Sharma C, Cococcia S, Ellis N, et al. Systematic review: Accuracy of the enhanced liver fibrosis test for diagnosing advanced liver fibrosis and cirrhosis. *J Gastroenterol Hepatol*. Jul 2021; 36(7): 1788-1802. PMID 33668077
36. Mózes FE, Lee JA, Vali Y, et al. Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis. *Lancet Gastroenterol Hepatol*. Aug 2023; 8(8): 704-713. PMID 37290471
37. López Tórriz SM, Ayala CO, Ruggiro PB, et al. Accuracy of prognostic serological biomarkers in predicting liver fibrosis severity in people with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of over 40,000 participants. *Front Nutr*. 2024; 11: 1284509. PMID 38419854
38. Huttman M, Parigi TL, Zoncapè M, et al. Liver fibrosis stage based on the four factors (FIB-4) score or Forns index in adults with chronic hepatitis C. *Cochrane Database Syst Rev*. Aug 13 2024; 8(8): CD011929. PMID 39136280
39. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. *Hepatology*. Aug 2003; 38(2): 518-26. PMID 12883497
40. Giannini EG, Zaman A, Ceppa P, et al. A simple approach to noninvasively identifying significant fibrosis in chronic hepatitis C patients in clinical practice. *J Clin Gastroenterol*. Jul 2006; 40(6): 521-7. PMID 16825935
41. Bourliere M, Penaranda G, Renou C, et al. Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies. *J Viral Hepat*. Oct 2006; 13(10): 659-70. PMID 16970597
42. Zarski JP, Sturm N, Guechot J, et al. Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study. *J Hepatol*. Jan 2012; 56(1): 55-62. PMID 21781944
43. Sebastiani G, Halfon P, Castera L, et al. SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. *Hepatology*. Jun 2009; 49(6): 1821-7. PMID 19291784
44. Boursier J, de Ledinghen V, Zarski JP, et al. Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive. *Hepatology*. Jan 2012; 55(1): 58-67. PMID 21898504
45. Rosenberg WM, Voelker M, Thiel R, et al. Serum markers detect the presence of liver fibrosis: a cohort study. *Gastroenterology*. Dec 2004; 127(6): 1704-13. PMID 15578508
46. Siemens Healthineers. Liver Fibrosis Assays: Enhanced Liver Fibrosis (ELF) Test. <https://www.siemens-healthineers.com/laboratory-diagnostics/assays-by-diseases-conditions/liver-disease/elf-test>. Accessed September 30, 2024.
47. Younossi ZM, Felix S, Jeffers T, et al. Performance of the Enhanced Liver Fibrosis Test to Estimate Advanced Fibrosis Among Patients With Nonalcoholic Fatty Liver Disease. *JAMA Netw Open*. Sep 01 2021; 4(9): e2123923. PMID 34529067
48. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. *Hepatology*. Jun 2006; 43(6): 1317-25. PMID 16729309

49. Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. *Hepatology*. Jul 2007; 46(1): 32-6. PMID 17567829
50. Yan LT, Wang LL, Yao J, et al. Total bile acid-to-cholesterol ratio as a novel noninvasive marker for significant liver fibrosis and cirrhosis in patients with non-cholestatic chronic hepatitis B virus infection. *Medicine (Baltimore)*. Feb 2020; 99(8): e19248. PMID 32080129
51. Klüppel M, Adler W, Schellhaas B, et al. Prognostic relevance of ARFI elastography in comparison to liver histology and the FIB-4 score. *Ultraschall Med*. Jun 2024; 45(3): 316-322. PMID 38171381
52. Cianci N, Subhani M, Hill T, et al. Prognostic non-invasive biomarkers for all-cause mortality in non-alcoholic fatty liver disease: A systematic review and meta-analysis. *World J Hepatol*. May 27 2022; 14(5): 1025-1037. PMID 35721296
53. Sanyal AJ, Harrison SA, Ratziu V, et al. The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials. *Hepatology*. Dec 2019; 70(6): 1913-1927. PMID 30993748
54. National Institute for Health and Care Excellence (NICE). Non-alcoholic fatty liver disease (NAFLD): assessment and management [NG49]. 2016; <https://www.nice.org.uk/guidance/ng49>. Accessed September 30, 2024.
55. Brener S. Transient Elastography for Assessment of Liver Fibrosis and Steatosis: An Evidence-Based Analysis. *Ont Health Technol Assess Ser*. 2015; 15(18): 1-45. PMID 26664664
56. Bota S, Herkner H, Sporea I, et al. Meta-analysis: ARFI elastography versus transient elastography for the evaluation of liver fibrosis. *Liver Int*. Sep 2013; 33(8): 1138-47. PMID 23859217
57. Chon YE, Choi EH, Song KJ, et al. Performance of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B: a meta-analysis. *PLoS One*. 2012; 7(9): e44930. PMID 23049764
58. Friedrich-Rust M, Ong MF, Martens S, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. *Gastroenterology*. Apr 2008; 134(4): 960-74. PMID 18395077
59. Kwok R, Tse YK, Wong GL, et al. Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease--the role of transient elastography and plasma cytokeratin-18 fragments. *Aliment Pharmacol Ther*. Feb 2014; 39(3): 254-69. PMID 24308774
60. Poynard T, Morra R, Ingiliz P, et al. Assessment of liver fibrosis: noninvasive means. *Saudi J Gastroenterol*. Oct 2008; 14(4): 163-73. PMID 19568532
61. Poynard T, Ngo Y, Munteanu M, et al. Noninvasive Markers of Hepatic Fibrosis in Chronic Hepatitis B. *Curr Hepat Rep*. Jun 2011; 10(2): 87-97. PMID 21654911
62. Shaheen AA, Wan AF, Myers RP. FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. *Am J Gastroenterol*. Nov 2007; 102(11): 2589-600. PMID 17850410
63. Shi KQ, Tang JZ, Zhu XL, et al. Controlled attenuation parameter for the detection of steatosis severity in chronic liver disease: a meta-analysis of diagnostic accuracy. *J Gastroenterol Hepatol*. Jun 2014; 29(6): 1149-58. PMID 24476011

64. Steadman R, Myers RP, Leggett L, et al. A health technology assessment of transient elastography in adult liver disease. *Can J Gastroenterol*. Mar 2013; 27(3): 149-58. PMID 23516679
65. Stebbing J, Farouk L, Panos G, et al. A meta-analysis of transient elastography for the detection of hepatic fibrosis. *J Clin Gastroenterol*. Mar 2010; 44(3): 214-9. PMID 19745758
66. Talwalkar JA, Kurtz DM, Schoenleber SJ, et al. Ultrasound-based transient elastography for the detection of hepatic fibrosis: systematic review and meta-analysis. *Clin Gastroenterol Hepatol*. Oct 2007; 5(10): 1214-20. PMID 17916549
67. Tsochatzis EA, Gurusamy KS, Ntaoula S, et al. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. *J Hepatol*. Apr 2011; 54(4): 650-9. PMID 21146892
68. Tsochatzis EA, Crossan C, Longworth L, et al. Cost-effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis C. *Hepatology*. Sep 2014; 60(3): 832-43. PMID 25043847
69. Xu XY, Wang WS, Zhang QM, et al. Performance of common imaging techniques vs serum biomarkers in assessing fibrosis in patients with chronic hepatitis B: A systematic review and meta-analysis. *World J Clin Cases*. Aug 06 2019; 7(15): 2022-2037. PMID 31423434
70. Cai C, Song X, Chen X, et al. Transient Elastography in Alcoholic Liver Disease and Nonalcoholic Fatty Liver Disease: A Systemic Review and Meta-Analysis. *Can J Gastroenterol Hepatol*. 2021; 2021: 8859338. PMID 33542909
71. Geng XX, Huang RG, Lin JM, et al. Transient elastography in clinical detection of liver cirrhosis: A systematic review and meta-analysis. *Saudi J Gastroenterol*. 2016; 22(4): 294-303. PMID 27488324
72. Jiang W, Huang S, Teng H, et al. Diagnostic accuracy of point shear wave elastography and transient elastography for staging hepatic fibrosis in patients with non-alcoholic fatty liver disease: a meta-analysis. *BMJ Open*. Aug 23 2018; 8(8): e021787. PMID 30139901
73. Li Y, Huang YS, Wang ZZ, et al. Systematic review with meta-analysis: the diagnostic accuracy of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B. *Aliment Pharmacol Ther*. Feb 2016; 43(4): 458-69. PMID 26669632
74. Njei B, McCarty TR, Luk J, et al. Use of transient elastography in patients with HIV-HCV coinfection: A systematic review and meta-analysis. *J Gastroenterol Hepatol*. Oct 2016; 31(10): 1684-1693. PMID 26952020
75. Pavlov CS, Casazza G, Nikolova D, et al. Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver disease. *Cochrane Database Syst Rev*. Jan 22 2015; 1(1): CD010542. PMID 25612182
76. Xu X, Su Y, Song R, et al. Performance of transient elastography assessing fibrosis of single hepatitis B virus infection: a systematic review and meta-analysis of a diagnostic test. *Hepatol Int*. Oct 2015; 9(4): 558-66. PMID 26187292
77. Abdel Alem S, Elsharkawy A, El Akel W, et al. Liver stiffness measurements and FIB-4 are predictors of response to sofosbuvir-based treatment regimens in 7256 chronic HCV patients. *Expert Rev Gastroenterol Hepatol*. Oct 2019; 13(10): 1009-1016. PMID 31418303

78. Azizi N, Naghibi H, Shakiba M, et al. Evaluation of MRI proton density fat fraction in hepatic steatosis: a systematic review and meta-analysis. *Eur Radiol*. Sep 10 2024. PMID 39254718
79. Beyer C, Hutton C, Andersson A, et al. Comparison between magnetic resonance and ultrasound-derived indicators of hepatic steatosis in a pooled NAFLD cohort. *PLoS One*. 2021; 16(4): e0249491. PMID 33793651
80. Imajo K, Tetlow L, Dennis A, et al. Quantitative multiparametric magnetic resonance imaging can aid non-alcoholic steatohepatitis diagnosis in a Japanese cohort. *World J Gastroenterol*. Feb 21 2021; 27(7): 609-623. PMID 33642832
81. McDonald N, Eddowes PJ, Hodson J, et al. Multiparametric magnetic resonance imaging for quantitation of liver disease: a two-centre cross-sectional observational study. *Sci Rep*. Jun 15 2018; 8(1): 9189. PMID 29907829
82. Jayaswal ANA, Levick C, Selvaraj EA, et al. Prognostic value of multiparametric magnetic resonance imaging, transient elastography and blood-based fibrosis markers in patients with chronic liver disease. *Liver Int*. Dec 2020; 40(12): 3071-3082. PMID 32730664
83. Pavlides M, Banerjee R, Sellwood J, et al. Multiparametric magnetic resonance imaging predicts clinical outcomes in patients with chronic liver disease. *J Hepatol*. Feb 2016; 64(2): 308-315. PMID 26471505
84. Harrison SA, Dennis A, Fiore MM, et al. Utility and variability of three non-invasive liver fibrosis imaging modalities to evaluate efficacy of GR-MD-02 in subjects with NASH and bridging fibrosis during a phase-2 randomized clinical trial. *PLoS One*. 2018; 13(9): e0203054. PMID 30192782
85. Nakajima A, Eguchi Y, Yoneda M, et al. Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor  $\alpha$  modulator (SPPARM $\alpha$ ), versus placebo in patients with non-alcoholic fatty liver disease. *Aliment Pharmacol Ther*. Nov 2021; 54(10): 1263-1277. PMID 34528723
86. Jayaswal ANA, Levick C, Collier J, et al. Liver cT 1 decreases following direct-acting antiviral therapy in patients with chronic hepatitis C virus. *Abdom Radiol (NY)*. May 2021; 46(5): 1947-1957. PMID 33247768
87. Janowski K, Shumbayawonda E, Dennis A, et al. Multiparametric MRI as a Noninvasive Monitoring Tool for Children With Autoimmune Hepatitis. *J Pediatr Gastroenterol Nutr*. Jan 01 2021; 72(1): 108-114. PMID 32925554
88. Arndtz K, Shumbayawonda E, Hodson J, et al. Multiparametric Magnetic Resonance Imaging, Autoimmune Hepatitis, and Prediction of Disease Activity. *Hepatol Commun*. Jun 2021; 5(6): 1009-1020. PMID 34141986
89. Bradley C, Scott RA, Cox E, et al. Short-term changes observed in multiparametric liver MRI following therapy with direct-acting antivirals in chronic hepatitis C virus patients. *Eur Radiol*. Jun 2019; 29(6): 3100-3107. PMID 30506214
90. Heneghan MA, Shumbayawonda E, Dennis A, et al. Quantitative magnetic resonance imaging to aid clinical decision making in autoimmune hepatitis. *EClinicalMedicine*. Apr 2022; 46: 101325. PMID 35340625
91. Guo Y, Parthasarathy S, Goyal P, et al. Magnetic resonance elastography and acoustic radiation force impulse for staging hepatic fibrosis: a meta-analysis. *Abdom Imaging*. Apr 2015; 40(4): 818-34. PMID 24711064
92. Hu X, Qiu L, Liu D, et al. Acoustic Radiation Force Impulse (ARFI) Elastography for non-invasive evaluation of hepatic fibrosis in chronic hepatitis B and C patients: a



- systematic review and meta-analysis. *Med Ultrason*. Jan 31 2017; 19(1): 23-31. PMID 28180193
93. Lin Y, Li H, Jin C, et al. The diagnostic accuracy of liver fibrosis in non-viral liver diseases using acoustic radiation force impulse elastography: A systematic review and meta-analysis. *PLoS One*. 2020; 15(1): e0227358. PMID 31940395
  94. Liu H, Fu J, Hong R, et al. Acoustic Radiation Force Impulse Elastography for the Non-Invasive Evaluation of Hepatic Fibrosis in Non-Alcoholic Fatty Liver Disease Patients: A Systematic Review Meta-Analysis. *PLoS One*. 2015; 10(7): e0127782. PMID 26131717
  95. Nierhoff J, Chávez Ortiz AA, Herrmann E, et al. The efficiency of acoustic radiation force impulse imaging for the staging of liver fibrosis: a meta-analysis. *Eur Radiol*. Nov 2013; 23(11): 3040-53. PMID 23801420
  96. Singh S, Venkatesh SK, Wang Z, et al. Diagnostic performance of magnetic resonance elastography in staging liver fibrosis: a systematic review and meta-analysis of individual participant data. *Clin Gastroenterol Hepatol*. Mar 2015; 13(3): 440-451.e6. PMID 25305349
  97. Singh S, Venkatesh SK, Loomba R, et al. Magnetic resonance elastography for staging liver fibrosis in non-alcoholic fatty liver disease: a diagnostic accuracy systematic review and individual participant data pooled analysis. *Eur Radiol*. May 2016; 26(5): 1431-40. PMID 26314479
  98. Xiao G, Zhu S, Xiao X, et al. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis. *Hepatology*. Nov 2017; 66(5): 1486-1501. PMID 28586172
  99. Kobayashi K, Nakao H, Nishiyama T, et al. Diagnostic accuracy of real-time tissue elastography for the staging of liver fibrosis: a meta-analysis. *Eur Radiol*. Jan 2015; 25(1): 230-8. PMID 25149296
  100. Hong H, Li J, Jin Y, et al. Performance of real-time elastography for the staging of hepatic fibrosis: a meta-analysis. *PLoS One*. 2014; 9(12): e115702. PMID 25541695
  101. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. *Hepatology*. Jan 2018; 67(1): 328-357. PMID 28714183
  102. Kanwal F, Shubrook JH, Adams LA, et al. Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. *Gastroenterology*. Nov 2021; 161(5): 1657-1669. PMID 34602251
  103. Wattacheril JJ, Abdelmalek MF, Lim JK, et al. AGA Clinical Practice Update on the Role of Noninvasive Biomarkers in the Evaluation and Management of Nonalcoholic Fatty Liver Disease: Expert Review. *Gastroenterology*. Oct 2023; 165(4): 1080-1088. PMID 37542503
  104. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. *Hepatology*. May 01 2023; 77(5): 1797-1835. PMID 36727674
  105. Kanwal F, Neuschwander-Tetri BA, Loomba R, et al. Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease. *Hepatology*. May 01 2024; 79(5): 1212-1219. PMID 38445559
  106. Cusi K, Isaacs S, Barb D, et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American

- Association for the Study of Liver Diseases (AASLD). *Endocr Pract.* May 2022; 28(5): 528-562. PMID 35569886
107. Sterling RK, Patel K, Duarte-Rojo A, et al. AASLD Practice Guideline on blood-based noninvasive liver disease assessment of hepatic fibrosis and steatosis. *Hepatology.* Mar 15 2024. PMID 38489523
108. Sterling RK, Duarte-Rojo A, Patel K, et al. AASLD Practice Guideline on imaging-based noninvasive liver disease assessment of hepatic fibrosis and steatosis. *Hepatology.* Mar 15 2024. PMID 38489518
109. Singh S, Muir AJ, Dieterich DT, et al. American Gastroenterological Association Institute Technical Review on the Role of Elastography in Chronic Liver Diseases. *Gastroenterology.* May 2017; 152(6): 1544-1577. PMID 28442120
110. American Association for the Study of Liver Diseases, Infectious Diseases Society of America. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. HCV Testing and Linkage to Care. Last updated October 24, 2022; <https://www.hcvguidelines.org>. Accessed September 30, 2024.
111. Bhattacharya D, Aronsohn A, Price J, et al. Hepatitis C Guidance 2023 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. *Clin Infect Dis.* May 25 2023. PMID 37229695
112. National Institute for Health and Care Excellence (NICE). Hepatitis B (chronic): diagnosis and management [CG165]. 2017; <https://www.nice.org.uk/guidance/cg165>. Accessed September 29, 2024.
113. Bashir MR, Horowitz JM, Kamel IR, et al. ACR Appropriateness Criteria® Chronic Liver Disease. *J Am Coll Radiol.* May 2020; 17(5S): S70-S80. PMID 32370979
114. Owens DK, Davidson KW, Krist AH, et al. Screening for Hepatitis C Virus Infection in Adolescents and Adults: US Preventive Services Task Force Recommendation Statement. *JAMA.* Mar 10 2020; 323(10): 970-975. PMID 32119076

## **OTHER REFERENCES**

1. Blue Cross and Blue Shield of Kansas Radiology Liaison Committee Consent Ballot, July 2018.
2. Blue Cross and Blue Shield of Kansas Radiology Liaison Committee, April 2016; July 2017; May 2019, July 2020, January 2021.
3. Blue Cross and Blue Shield of Kansas Internal Medicine Liaison Committee, August 2018; February 2019, June 2020, June 2023.